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Abstract 
Insulin-like growth factor-II (IGF-II) is a member of a family of growth 
factors with structural homology to proinsulin. In fish, the basic mechanism of the 
growth hormone (GH)-IGF axis is shown to be operative but in a different manner. 
IGF-I exhibits GH dependence. Whether IGF-II is GH dependent or not depends on 
the fish species. IGF-II is a fetal growth factor in mammals but its physiological role 
has not been clearly identified in fish. To examine the phylogeny, biochemistry and 
molecular biology of IGFs in fish, common carp {Cyprinus carpio), a local tropical 
fish species, is chosen as the study model. Multiple cDNA forms of IGF-I and one 
form of IGF-II have been identified in other fish species such as rainbow trout. In 
common carp, however, only one form of IGF-I, the IEa2 form, has been identified 
thus far. In this study, the IGF-II cDNA in common carp has been cloned by a 
combination of polymerase chain reaction (PGR) and Rapid Amplification of cDNA 
Ends (RACE) techniques. A fragment of the common carp IGF-II cDNA was 
amplified by PGR using primers designed in the B- and D-domains. RACE was then 
employed to obtain the full-length sequence. At the amino acid level, the common 
carp IGF-II prohormone exhibits 76.6% identity to pro-IGF-II of salmon, 72.6% 
identity to tilapia, 79.1% identity to barramundi and 40.3% identity to human. The 
percentage nucleotide identity between the open reading frame (ORF) of the common 
carp IGF-II and the common carp IGF-IEa 2 cDNA sequence is 35.8%. Two 
transcripts of IGF-II were obtained in Northern hybridization analysis from ovary and 
larvae. The tissue distribution of IGF-II in common carp was also studied. In in 
vivo study of juvenile common carp, hepatic IGF-II shows GH-dependence, as 
measured by the ribonuclease protection assay. 
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論文撮要 
胰 島 素 樣 生 長 因 子 - I I ( I G F - I I ) 屬 生 長 因 子 家 族 . 該 家 族 成 員 與 胰 
島素原有結構同源性 .魚類生長激素（ G H ) - I G F 軸的基本作用模式與喷乳類相 
同 . 胰 島 素 生 長 因 子 - I ( I G F - I ) 呈 現 G H 的 依 賴 性 ， 至 於 I G F - I I 的 G H 的 
依 賴 性 則 要 視 乎 魚 的 種 類 而 定 . I G F - I I 是 喷 乳 類 胎 兒 的 生 長 因 子 ， 但 在 魚 的 生 
理作用仍未完全瞭解• 我 們 以 本 地 熱 帶 魚 類 一 經 魚 Q C y p r i n u s c a r p / o )作為 
研 究 對 象 ， 對 其 I G F 進 行 種 系 發 展 ， 生 物 化 學 及 分 子 生 物 學 研 究 . 據 報 道 虹 鱒 
發現了 4 種 I G F - 1 基 因 轉 錄 產 物 和 1 種 I G F - I I 基 因 轉 錄 產 物 ， 但 在 經 魚 至 今 
只發現了 1 種 I G F - I E a 2 基 因 轉 錄 產 物 . 本 研 究 中 ， 我 們 通 過 結 合 運 用 聚 合 嘛 
鏈 式 反 應 及 R A C E 的 技 術 ， 克 隆 了 經 魚 的 I G F - 1 1 基 因 轉 錄 產 物 . 我 們 在 B 及 D 
區域設計並合成一對引物，成功地擴增出經魚 I G F - I I —個片段，再利用 R A C E 
技術進一步獲取其全長 c D N A . 經序列分析，經魚和鱒魚，顧彳魚，驢魚及人類的 
I G F 讀 碼 框 就 基 酸 序 列 同 源 性 分 別 為 7 6 . 6%，72 . 6%, 79. 1 %及 4 0 . 3%. 經魚 
I G F - I I 及 I G F - I E a 2 c D N A的讀碼框核酸序列同源性達 3 5 . 8%. 在幼魚及印巢的 
N o r t h e r n 染 交 中 檢 出 兩 種 轉 錄 產 物 . 應 用 核 糖 核 酸 海 保 護 法 （ R P A ) 技 術 ， 對 
各 組 織 的 I G F - I I 信 使 核 糖 核 酸 的 表 達 水 平 亦 進 行 了 定 量 檢 查 . 通 過 對 幼 魚 體 
腔注射 G H ，發現 I G F - I I 呈現生長激素依賴性 . 
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Chapter 1 I n t r o d u c t i o n 
Chapter I: Introduction 
1.1 Literature Review 
Life never ends whenever growth is present. Most organisms grow 
throughout life but the most profound and visible periods of vertebrate growth are 
usually associated with the early stages of development. Numerous growth factors 
are involved in the growth process. Among them, insulin-like growth factor-II 
(IGF-II) is a fetal growth factor in mammals, but its physiological role has not been 
definitively established in fish. Perhaps the future route of research on IGF-II is best 
obtained by extrapolation from the past. 
IGFs were discovered in 1956 by William D. Salmon, Jr. and William H. 
Daughaday, who observed that the pituitary growth hormone (GH) in vitro did not 
correct the defect in the synthesis of matrix proteins obtained from 
hypophysectomized rats , whereas the serum of GH-treated hypophysectomized rats 
did (Salmon and Daughaday, 1957). Two years after this classical observation, 
Leonards called attention to the fact that less than 10% of the total insulin-like activity 
of serum could be neutralized by antibodies to insulin and the factors were termed 
nonsuppressible insulin-like activity (NSILA) (Froesch et al, 1966). By uniting 
1 
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research on GH dependent growth factors with studies on insulin-like substance as a 
mediator of the effects of GH, the somatomedin hypothesis (Daughaday et al, 1972) 
emerged. Initial biological studies of somatomedin were based on the use of crude 
serum extracts. Although they could not be extracted successfully, it was found that 
highly purified somatomedin stimulated glucose incorporation into fat as well as 
sulfate incorporation into cartilage like insulin (Froesch et al, 1976). Rapid and 
dramatic progress has been made during the 80，s; human IGF-I and IGF-II genes were 
cloned (Jansen et al, 1983; Jansen et al, 1985), IGF and insulin receptors have been 
characterized (MacDonald et al, 1988; Ullrich et al, 1986) and the importance of 
binding proteins have been recognized (Baxter and Martin, 1989; Elgin et al, 1987). 
It was later hypothesized that IGFs belong to an evolutionarily related gene 
family which includes insulin, IGF-I, IGF-II, relaxin, insect prothoracicotrophic 
hormone (PTTH) and molluscan insulin-related peptide (MIP) (Blundell and Humbel, 
1980; Smit et al, 1988). Prevailing theory on the evolution of this family suggests 
that an "early" insulin-like gene duplication gave rise to the "primary" family 
members including the modern insulin and IGF-I, and that IGF-I and II diverged 
during the evolution of mammals (Froesch et al, 1985). However, the detection of 
IGF-I in Xenopus (Kajimoto and Rotwein, 1990) and rainbow trout suggested that the 
gene duplication event leading to two IGFs occurred before the evolutionary 
2 
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divergence of birds and reptiles (Daughaday et al, 1985). 
1.1.1 An overview of IGFs 
IGFs are single-chain polypeptides that are initially translated as 
prepropeptides, and in this form resemble proinsulin, with a leader sequence 
N-terminal to the mature peptide sequence, then a B-, C-, A-, D-domain, then a 
E-domain trailer peptide C-terminal (Fig 1.1, Lowe, 1996). Similar to insulin, the 
propeptide leader which directs the newly synthesized IGF to the endoplasmic 
reticulum for eventual secretion, is proteolytically removed. However, the C 
connecting peptide between domains A and B remain linked together in the mature 
and secreted hormone in the serum. Very little is known, however, regarding the 
E-domain portion. 
3 
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Fig. 1.1 The structure of pro insu l in � IGF-I and IGF-IL The A chains (green) and B 
chains (red) are largely the same in all three molecules, as are the C chains (purple) in the two 
IGFs. In the case of insulin, a longer C chain is cleaved out during processing. Another 
similarity is the conservation of cysteines that provide disulfide bridges in the same positions 
within each peptide. The IGF's are unlike insulin in having short carboxyl-terminal D 
chains, and the proIGF's also contain carboxy-terminal extensions or E chains that are 
removed during processing (Lowe, 1996). 
4 
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1.1.2 Molecular biology of IGFs 
1.1.2.1 IGF-I and IGF-II genes and itiRNAs 
IGF-I and II are each the product of a single gene in mammals, localized in 
man on the long arm of chromosome 12 and on the short arm of chromosome 11 
respectively (Brissenden et al, 1984; Tricoli et al, 1984). The IGF-II gene is 
contiguous with the insulin gene whereas the gene for tyrosine hydroxylase is also 
contiguous with the insulin gene (O'Malley and Rotwein, 1988), the order being 
5'—tyrosine-hydroxylase—insulin—IGF-II—3' (Humbel, 1990). 
The human IGF-II gene spans about 30 kb and consists of four promotors, 
six non-coding exons (exons 1-6) and three protein-coding exons (exons 7-9) 
(Sussenbach, 1989) as shown in Fig. 1.2. Exon 7 encodes the propeptide and part of 
the B domain, which is similar to the exon 3 of the IGF-I gene. Exon 8 encodes the 
remainder of the B domain, the C, A, D domains and the amino terminus of E domain, 
which is analogous to exon 4 of the IGF-I gene. Exon 9 encodes the remainder of 
the E domain and the 3' UTR that is similar to exon 6 of the IGF-I gene. Gray et al. 
(1987) have found that the 5' ends of IGF-II cDNA isolated from adult liver differ 
radically from those of other tissues whereas a similar complexity in the transcription 
of the rat IGF-II gene has also been raised by Scares et al. (Scares et al, 1986). 
Nevertheless, various transcripts vary in their untranslated or even including 
5 
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E-domain only, thus they all code for the same BCAD domains of the peptide when 
finally processed. 
6 
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Fig. 1.2 Schematic representation of the human IGF genes and corresponding mRNAs. 
(Panel A) IGF-I gene with IC and IB represent the alternative initiation sites of transcription 
and solid blocks represent the coding regions. (Panel B) In the preproIGF-II the coding 
regions are indicated as black boxes whereas the 5' and 3' untranslated regions are donated as 
open boxes. The numbered boxes indicate the nine exons of the IGF-II gene. Vertical 
arrows correspond to promoters (P1-P4). 
Asterisks indicate polyadneylation sites. Patterns of differential leader exon usage, splicing 
and polyadenylation site usage in different IGF mRNA species and their sizes are shown in 
the lower portion of the figure (Sussenbach, 1989). 
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Exons 1 to 6 of the IGF-II gene are flanked by distinct promotors, which 
have been designated PI through 4 (Fig. 1.2). Transcripts initiated at the P2 and P3 
promotors predominate in most embryonic tissues. Hepatic transcripts, which are 
primarily responsible for circulating IGF-II, are initiated at the PI promoter after birth 
(Pagter-Holthuizen et al, 1988). Both the P2 and P3 promotors contain TATA 
elements as well as binding sites for transcription factors such as SPl, whereas PI 
lacks TATA motifs and exhibit disperse transcription initiation (Matsuguchi et al, 
1990). A possible modulator of IGF-II mRNA translatability is the generation of the 
1.8 kb fragment of the exon 7 sequence, in that removal of this 3'UTR sequence from 
the parental mRNA could affect the stability or translatability of the latter. Recent 
studies report that the 1.8 kb sequence is itself not translated (Nielsen and 
Christiansen, 1992). 
1.1.2.2 Amino acid sequences of IGF-II 
The first determination of IGF-II amino acid sequence was made in 1978 
(Rinderknecht and Humbel, 1978a) on the peptides isolated from 1 kg of an acetone 
powder of a Cohn fraction of human serum, together with IGF-I, based upon its 
insulin-like activity on adipose tissue. Amino acid sequences of IGFs from several 
other species have been determined and the primary structures of IGF-II from the 
eight species known today are listed in Fig. 1.3. In human, the structure of IGF-II 
8 
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exhibits about 70% nucleotide sequence homology with IGF-I and 50% nucleotide 
sequence homology with insulin (Daughaday et al, 1982) as shown in Fig. 1.4. It 
was also found that the recognition site for the type 1 receptor is similarly located to 
the one for the insulin receptor with the aromatic residues at position 23-25 (Cascieri 
et al, 1989a) definitely involved. 
Most of the IGF-II in the circulation is present in its mature 67-amino acid 
form which lacks the E peptide region, the function of which is unknown (Liu et al, 
1993). IGF- II has a molecular weight of 7500 (Bell et al., 1984) and circulates in 
human plasma bound to a large molecular weight carrier (binding) protein (IGFBP) 
(Rinderknecht and Humbel, 1976). The N-terminal part of IGF is required as a 
recognition site for binding to the IGF binding proteins; either deletion of the first 
three residues (Bagley et al, 1989) or subsitution of residues 3, 4, 15 and 16 (Bayne 
et al, 1988; Cascieri et al, 1989b) decreases the affinity drastically. 
The concentration of the separate E fragment in serum is higher than that of 
IGF-II itself, possibily because the former is cleared more slowly. Increased IGFBPs 
may increase the steady state level of IGF-II by protecting it from clearance, but do 
not affect the E domain because the E domain does not bind to IGF binding proteins 
or receptors (Straus et al, 1991). For example, an increase in IGFBP-1 can 
compensate for a decrease in IGF-II, but not for a decrease in the E domain. The 
9 
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presence of the E extension does not affect binding of IGF-II to the IGF receptors 
(Hammarberg et al, 1991). A probable product of differential processing of 
prepro-IGF, the truncated IGF-II lacking the amino-terminal alanine residue 
(Rinderknecht and Humbel, 1978a) has been found in fetal and adult human brain. 
However, evidence indicates that the accumulation of the reduced binding of the 
truncated form to IGF-binding proteins may be responsible for its increased biological 
potency (Ballard et al, 1987; Szabo et al, 1988). 
10 
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IGF-II Species B C A D 
Human Homo sapiens AYRPSETLCGGELVDTLQFVCGDRGFYF ttSRPASRVttSRRSftftR GIVEECCFRSCDLALLETYCA TPAKSE 
Chicken Gall us ga 11 us tt-GTA # VG-NttN-—IttN- KSV 
Z. f i n c h T. guttata AYGTA tt——VG-N#N——F#NR KSV —— 
Bovine Bos taurus # ——S--I#N ——##-
Porcine Sus scrofa # ——##-
Ovine Ovis aries • # ——S--I#1SI ——##- A 
Rat Rattus norvegicus S #——S--A#N —— 
Mouse Mus Musculus --G-G S tt ——S—-A#N —— 
Trout 0. myki ss EVASA A E tt——T--SN QN- N ——Q——K 
Salmon 0. kitsutch EVASA A E # T- — SN QN- N Q K 
Barramundi Lates calcarifer EMASA A E # T—-GSN—-PQN- N Q K 
G i l t h e a d Sparus auratus EVASA A E # T--GNN--PQN- N Q K 
T i l a p i a O. mossambicus EMASA A E #——T—-GNN--PQT- N — — Q — — K 
Sculpin Cottus scorpius EITSA A E ft T__GNN——NQN- N Q K 
Shark Squalus acanthiasEA-LE S I-AE V-KVVG-R#--##QN- LI V-PEAA 
Fig. 1.3 Amino acid sequences of IGF-II. Comparison of the human IGF-II amino 
acid sequence (Rinderknecht and Humbel, 1978b) (human) with those of chicken (Upton 
et al, 1995), Zebra finch (Holzenberger et al, 1997), bovine (Francis et al, 1988), 
porcine (Francis et al, 1989a), ovine (Francis et al, 1989b), rat (Marquardt et al, 1981), 
mouse (Stempien et al, 1986), trout (Shamblott and Chen, 1992), salmon (Palamarchuk et 
al-, 1997), barramundi (Collet et al, 1997), gilthead seabream (Duguay et al, 1996), 
tilapia (Chen et al, 1997), daddy sculpin (Loffing-Cueni et al, 1999) and shark (Duguay 
et al, 1995). 
Amino acid residues are given in single-letter code. Dashes signify residues identical to 
the top sequence. Gaps are indicated by “#”. The peptide domains are indicated at the 
top. 
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i _ 
Fig. 1.4 Amino acid sequence of human IGF-II. The shaded residues 
correspond to the homologous positions in the insulin amino acid sequence. (Cook 
et al, 1991) 
1.1.2.3 Imprinting of IGF-II 
A new level of complexity in the control of IGF-II expression has been 
added by the fact that the IGF-II gene is imprinted. It was demonstrated first in the 
mouse (DeChiara et al, 1990) and later in human (Giannoukakis et al, 1993) and in 
rat (Pedone el al., 1994) tissues that the paternally inherited allele is expressed and the 
maternally inherited allele is silent. This was clearly demonstrated by the phenotype 
of mice carrying a paternally inherited mutant allele of the IGF-II gene which resulted 
in a greatly reduced body size (DeChiara et ciL, 1990). Conversely, it was shown 
that fetal mice artifically overexpressing IGF-II have an increased growth phenotype 
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(Ward et al, 1994). In a subset of human Wilms' tumours and Beck with 
Wiedemann syndrome patients, it was further shown that loss of heterozygosity and 
duplication of the paternal allele can result in increased expression of IGF-II in 
tumours because in these instances both alleles are transcriptionally active (Ohlsson et 
al, 1994; Weksberg et al, 1993). 
Recent publications have addressed the question of whether there is a 
correlation between IGF-II promotor usage and the monoallelic or biallelic expression 
of the human IGF-II gene. Interestingly, it could be shown that the P2, P3 and P4 
IGF-II promotors are activated only on the paternal allele during prenatal and early 
postnatal development, while in human adult liver biallelic expression directed by PI 
is observed (Davies, 1994; Vu and Hoffman, 1994). Biallelic expression of the 
IGF-II gene was further detected in two cell regions of the central nervous system, the 
choroid plexus and leptomeninges (Ohlsson et al, 1994). The rat and the mouse 
IGF-II transcripts are derived from the three promotors on the paternal allele in all 
tissues examined with the exception of some regions of the central nervous system 
both in the rat (Pedone et al, 1994) and in the mouse (DeChiara et al, 1991; Hu et al, 
1995). This will be discussed in section 1.1.5. 
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1.1.3 IGF distribution in tissues and body fluids 
The discovery of IGF production in tissues other than the liver (D'Ercole et 
al, 1980) has confronted the classical somatomedin hypothesis (Daughaday et al, 
1972; Salmon and Daughaday, 1957). It is now generally accepted that IGF-I and -II 
both act as endocrine hormones via the circulation and as paracrine and autocrine 
growth factors locally. 
1.1.3.1 IGF in serum 
Nowhere else in the body are the concentrations of IGF as high as in blood. 
Standard procedures for their determination have been the radioimmunoassay for 
IGF-I (Furlanetto and Marino, 1987) and the radioreceptor assay for IGF-II 
(Daughaday, 1987). Moreover, with the advent of commercially available 
recombinant IGF-I and IGF-II, and Cig cartridges (Sep Pak) which separate IGFs 
from binding proteins (Kao et al, 1988), the classical difficulties in the measurement 
of serum IGFs, such as the interference of binding proteins and the 
cross-contamination of different IGFs, have been overcome. Nevertheless, 
information about serum levels of IGF-II during gestation and at birth is still 
conflicting because of substantial interspecies difference and the variety of assays that 
have been used to measure its levels. 
In the rat (Moses et al, 1983) and in the lamb (Gluckman and Butler, 
14 
Chapter 1 I n t r o d u c t i o n 
1983), fetal serum IGF-I is much lower than in adult serum, whereas high 
concentrations of IGF-II in the fetus fall dramatically just before birth. Similarly, it 
has been reported (Daughaday et al, 1982; Daughaday and Rotwein, 1989) that the 
levels of IGF-II in human umbilical cord serum, when measured by a multiplication 
stimulating activity (MSA) receptor assay, are elevated in early gestation, fall after 
birth (Daughaday et al, 1986) and that the IGF-II level in serum reaches a nadir at 25 
days of life. Together with the observations on the developmental switch from 
IGF-II to IGF-I in culture of rat fibroblasts (Adams et al, 1983), evidence supported 
that IGF-II is primarily a fetal somatomedin and IGF-I a postnatal somatomedin. 
However, on the other hand, some findings in human suggest that both IGF-I and 
IGF-II are low in fetal serum and IGF-II persists at high levels into adulthood (Ashton 
et al, 1985; Bennett et al. 1983; Enberg and Hall, 1984). Zapfe/. al. (1981), using a 
human radioimmunoassay, even found that IGF-II level in umbilical cord serum are 
lower than those in adults which contrast with the finding of Daughaday et al. (1986). 
As the concentrations of the circulating IGFs (endocrine) and locally 
secreted (paracrine and autocrine) IGFs are yet to be correctly measured, the activity 
of IGF at the receptor level is probably not only determined by its concentration but 
also by the number of receptors and by the presence of IGF binding proteins. 
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1.1.3.2 IGF binding proteins 
In the attempts to purify IGF-I and IGF-II from serum, investigators found 
that the IGFs were bound to high molecular weight carrier proteins with high affinity. 
In human serum, six IGF binding proteins (IGFBP 1-6) have now been identified 
through N-terminal protein sequencing and/ or cDNA nucleotide sequencing (Martin 
and Baxter, 1986; Moses et al, 1979; Povoa et al, 1984). They all share structural 
homology with each other and specifically bind the IGFs, with negligible affinity for 
insulin (Jones and Clemmons, 1995). The mature proteins of the IGFBPs each 
consist of 200 to 300 amino acids, with signal sequences of 20 to 40 amino acids. 
The IGFBPs have 18 cysteine residues in their amino- and carboxy-terminal ends 
whose alignment is conserved, suggesting disulfide bonding may be important in 
forming the specific high-affinity IGF binding site. An exception is IGFBP-6, which 
lacks 2 and 4 of the homologous cysteines in the rat and human, respectively. In 
addition to the 18 cysteines, two additional cysteines are present in rat and human 
IGFBP-4. IGFBP-1 and - 2 contain an RGD sequence in their carboxy-terminal end, 
which is found in many extracellular matrix proteins and often serves as a recognition 
sequence for cell surface integrin receptors. Four of the IGFBPs (3 through 6) are 
glycosylated to varying degrees, which may be important for adherence to cell 
surfaces (Cohick and Clemmons, 1993). 
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The IGFBPs have been proposed to have four major functions that are 
essential to coordinate and regulate the biological activities of the IGFs. These are: 
(1) to act as transport proteins in plasma and to control the efflux of IGFs from the 
vascular space; (2) to prolong the half-lives of the IGFs and regulate their metabolic 
clearance; (3) to provide a means of tissue- and cell type-specific localization; and (4) 
to directly modulate interaction of the IGFs with their receptors and thereby indirectly 
control biological actions. A summary of proposed functions of IGFBPs is shown in 
Table 1.1 (Jones and Clemmons, 1995). Current knowledge of proposed biological 
actions of each IGFBP are described below individually. 
IGFBP-1 has been shown to have a higher affinity for IGF-I than for IGF-II 
(Baxter et al, 1987). Most studies that have shown inhibition of IGF activity by 
IGFBP-1 used cell culture systems under serum-free conditions. For optimal activity, 
such potentiation requires the presence of primarily dephosphorylated IGFBP-1, as 
well as binding of IGF to both the IGF receptor and IGFBP-1. 
IGFBP-2 has been much less extensively studied than IGFBP-1. It 
preferentially binds IGF-II (Baxter and Martin, 1989) and it appears to inhibit IGF 
actions (Ross et al, 1989), particularly those of IGF-II, although in certain specific 
cell types it can be a modest stimulator of IGF-I action (Bar et al, 1989). 
IGFBP-3 appears to bind both IGF-I and II with equal affinity (Baxter and 
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Martin, 1989). The recent IGF-I antibody studies using whole animal (Stewart el al., 
1993) suggest that IGFBP-3 in serum will potentiate IGF action. In contrast, IGF 
analog infusion studies suggest that constitutive expression of IGFBPs in some organs, 
such as gut, may have a net inhibitory effect on IGF action (Cascieri et al, 1988; 
Cascieri et al. 1989a). Therefore, whether the net effect of the binding proteins is 
inhibitory or stimulatory is still conflicting with the current in vivo data. 
IGFBP-4 functions only as an inhibitor of IGF action (Kiefer et al, 1992), 
and that its main function is perhaps to protect cells from overstimulation by IGFs or 
to allow activation of alternate transmembrane siginalling pathways that are inhibited 
by IGF exposure. 
IGFBP-5 potentiates IGF-I's effect on DNA synthesis (Jones et al, 1993). 
Cell surface association of IGFBP-5 may also mediate its ability to potentiate IGF 
actions, and in this regard it is similar to IGFBP-3. The lowering of IGF binding 
affinity, by cell surface association, or protelytic cleavage (Andress et al, 1993), may 
also be an important factor in regulating the ability of IGFBP-5 to potentiate IGF 
actions. 
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Table 1.1 IGFBP functions 
IGFBP functions IGFBP-1 IGFBP-2 IGFBP-3 IGFBP-4 IGFBP-5 IGFBP-6 
Serum carrier Minor (insulin Significant (GH Major (ALS Minimal Minimal Minimal 
repressible) repressible) complex) 
(IGF/GH 
inducible) 
Pericellular Cell surface ( a5p l Undetermined Cell surface ECM, cell surface 
localization integrin) 
Basement membrane 
IGF potentiation + + + (preincubation) - + (ECM associated) 
(Nonphosphorylated) 
IGF inhibition + (Phosphorylated) + � + . 
1.1.4 IGF receptors 
The family of receptors which mediate IGF actions include the Type I and 
Type II IGF receptors (Fig. 1.5) and the insulin receptor. The IGF-I receptor, also 
known as type 1 IGF receptor, has a high degree of homology with the insulin 
receptor and is the only IGF receptor to definitely possess IGF-mediated signaling 
functions. The IGF-II receptor, which is also known as the type 2 IGF receptor, is 
identical to the cation-independent mannose 6-phosphate (M-6-P) receptor, which 
functions in the trafficking of lysosomal enzymes but has no known IGF signaling 
function. The insulin receptor can also bind the IGFs with low affinity, and hybrid 
the IGF/ insulin receptors have been isolated that bind the IGFs and potentially 
transmit a cytoplasmic signal, at least in vitro (Treadway et aL, 1991; Treadway et al., 
1992). 
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1.1.4.2 Ligaiid binding of the IGF receptors 
The IGF-II/ M-6-P receptor is a monomeric receptor that binds to M-6-P 
residues on lysosomal enzymes. Membrane-bound IGF-II receptors in the 
trans-Golgi network transolacte newly synthesized lysosomal enzymes into 
endosomes. Receptors localized on the cell surface bind M-6-P containing 
extracellular glycoproteins, which are then endocytosed into endosomes. In addition 
to lysosomal enzymes, the other Man-6-P containing gycoproteins recognized by 
plasma membrane receptors include renin, proliferin, tyroglobulin, and the latent form 
of transforming growth factor-(3 (TGF-|3). Binding of latent TGF-P to cell surface 
IGF-II receptors has been shown to result in cleavage of the inactive latent form into 
active TGF-P (Dennis and Rifkin, 1991). In adipocytes, insulin stimulation causes a 
redistribution of IGF-II receptors from intracellular locations to the plasma membrane, 
acting through the insulin receptor (Lonnroth et al, 1987). In fibroblasts, 
stimulation with IGF-I, IGF-II and insulin, signaling through the IGF-I receptor, and 
Man-6-P and IGF-II, signaling through the IGF-II receptor, induced an increase in the 
number of IGF-II receptors localized at the cell surface (Braulke et al, 1988). 
Cell surface IGF-II receptors bind IGF-II with high affinity with a reported 
Kd ranging from 0.017 to 0.4 nM (Nissley et al, 1991). Affinity for IGF-I is more 
than 500-fold lower, and the receptor does not bind insulin. The binding site for 
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IGF-II is distinct from that for M-6-P and M-6-P containing glycoproteins, and IGF-II 
can bind simultaneously with the M-6-P containing ligands (Braulke et al, 1988). 
However, the binding of certain lysosomal enzymes can interfere noncompetitively 
with IGF-II binding; conversely, IGF-II binding can inhibit enzyme binding (Kiess et 
al, 1988; Kiess et al, 1990). Binding of IGF-II to the IGF-II receptor causes 
internalization and degradation of the growth factor and this process is inhibited by 
lysosomal enzymes (Oka and Czech, 1986). The extracellular domain of the IGF-II 
receptor is proteolytically cleaved in cell culture and released in soluble form into the 
medium (Clairmont and Czech, 1991). This soluble form is also present in the 
serum whose levels may be developmentally regulated (Bobek et al, 1992). The 
physiological significance of the soluble IGF-II receptors is unknown, although it may 
act as a carrier for IGF-II. Significantly, IGF-II does not bind to the 
cation-independent M-6-P receptor of nonmammalian species, so any physiological 
function of this receptor in mediating IGF-II effects would have evolved after 
mammals diverged from other vertebrate is interested (Clairmont and Czech, 1989). 
1.1.4.3 Signal transduction and biological response 
The function of the IGF-II receptor as a scavenger receptor mediating the 
uptake and degradation of IGF-II is well accepted. It is less clear whether any of the 
biological actions of IGF-II are mediated by this receptor. Although there are reports 
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on biological effects of IGF-II via the type 2 IGF receptor (Roth, 1988), the results are 
difficult to interpret. The type 2 IGF receptor can be grouped into the class of 
membrane receptors involved in nutrient transport such as the low-density lipoprotein 
receptor that contrast with those of the growth factor type such as the insulin and the 
type 1 IGF receptor. Typical for the former type of receptors is the short cytoplasmic 
domain, the lack of tyrosine autokinase activity, the principal occurrence in 
intracellular membranes and a ligand-independent membrane cycling (Oka and Czech, 
1986). That IGF-II might associate with type 2 IGF receptor not for a growth signal 
but for degradation has been shown in experiments using anti-(type 2 IGF receptor) 
antibodies which inhibited IGF-II degradation by more than 90% (Kiess et al, 1987). 
Further support for the concept of a non-growth receptor comes from the fact, as 
previously mentioned, that M-6-P receptors of chickens and frogs fail to bind IGF-II 
(Canfield and Kornfeld, 1989; Clairmont and Czech, 1989). 
The failure to signal a growth effect dose of course does not exclude a 
relevant function in the action of IGF-II. It has long been known that insulin 
increases the binding of IGF-II to the type 2 IGF receptor in fat and hepatoma cells 
(Oppenheimer et al, 1983; Zapf et al, 1978). Apparently, IGF-II as well as 
27 
[Leu ]IGF-II stimulated migration of rhabdomyosarcoma cells, and the effect was 
not blocked by aIR-3 (Minniti et al, 1992). This strongly suggested that the 
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migration-stimulating effect was mediated by the IGF-II receptor. Intracellular 
biochemical responses have been proposed to result from the binding of IGF-II to 
IGF-II receptors. These receptors have been shown to be coupled to G i � � a 
GTP-binding protein (G protein). In phospholipid vesicles, IGF-II directly couples 
purified rat IGF-II receptor with porcine Gi�(Nishimoto et al, 1989). 
Despite the encouraging progress, we are far from a unified and clear 
picture of the physiological roles of IGF-II and its receptor. So far, we can only 
conclude that this receptor can clearly mediate uptake and degradation of IGF-II, and 
there has been a gradual accumulation of evidence that it may also mediate some of 
the actions of IGF-II. Loss of this receptor in mice is associated with fetal death in 
utero (Barlow et al, 1991; DeChiara et al, 1991) nucleotide sequence. Signaling 
via the IGF-II receptor may involve GTP-binding protein activation. 
1.1.5 Biological effects of IGF 
The ability of IGF-I to promote somatic growth in fish was 
demonstrated in vivo (McCormick et al, 1992). In vitro, IGF-I was found to 
stimulate DNA synthesis and proteoglycan synthesis in skeletal tissues of fish (Duan 
and Hirano, 1992), as well as protein synthesis in muscles of fish (Negatu and Meier, 
1995). On the other hand, the precise biological role of IGF-II in fetal growth 
remains undefined. The hypothesis that IGF-II plays a crucial role during 
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mammalian fetal development (D'Ercole and Underwood, 1981; Daughaday and 
Rotwein, 1989) has arisen from its being the predominant IGF in fetal circulation 
(D'Ercole, 1987; Sara and Hall, 1990), the striking changes in the pattern of IGF-II 
gene expression in tissues at different gestational ages (Rosen et al, 1993), and the 
fact that circulating levels of IGF-II are high before birth and then decline afterwards 
(Moses et al, 1979). In fact, serum IGF-II concentrations are nearly three times 
greater than the level of IGF-I in the rat fetus (Kim et al, 1993). IGF-II and its 
mRNA are present in most fetal tissues (D'Ercole et al, l980;Fant et al, 1986), as 
well as are IGF-II receptors and binding proteins. IGF-II also exerts mitogenic 
effects and promotes differentiation in fetal cells in vitro (D'Ercole, 1991). 
IGF-II not only acts as a circulating hormone, but also functions as a 
paracrine and/ or autocrine growth factor for the cells which secrete it or for 
neighboring ones (Whitman and Melton, 1989). Therefore, high circulating levels 
(endocrine) of IGF-II would not necessarily be required during fetal life to sustain 
fetal growth (D'Ercole et al, 1980;Frankenne et al, 1988). Some investigators have 
proposed that IGF-II is the somatomedin that regulates fetal growth, whereas IGF-I is 
the corresponding growth factor after birth (Adams et al, 1983; Humbel 1990; Moses 
et al, 1979; Shinar et al, 1993). 
The IGFs have an important role in the progression of some cells through 
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the cell cycle (Leof et al, 1980; Stiles et al, 1979). Van Wyk (1981) showed that 
the mode of action of many growth factors occurs at a specific point within the cell 
cycle of proliferation in which the cell leaves the resting (quiescent) state of Go, 
progresses through Gi (Gap 1, absence of DNA synthesis), undergoes DNA synthesis 
(S phase), enters G2 (synthesis of mRNAs and proteins necessary for mitosis), and 
divides into two cells during mitosis (M phase) (Wyk et al, 1981). IGF-II affects 
the progression of a cell through the second half of G] and entry into S phase (Hill, 
1992). It often acts synergistically with other growth factors that have specific 
actions at other times during the cell cycle (Hill, 1992). 
Most convincing of all that IGF-II has an essential role in normal growth 
are the studies of mice in which growth retardation occurs after the gene for IGF-II 
has been deleted (DeChiara et al, 1990; Rotwein and Hall, 1990). To more directly 
examined the developmental role of IGF-II, DeChiara et al. (1990) disrupted one of 
the IGF-II alleles in cultured mouse embryonic stem (ES) cells (Evans and Kaufman, 
1981; Martin 1981; Robertson and Bradley, 1986) by gene targeting (Thomas and 
Capecchi, 1987). They constructed chimeric animals (individuals possessing cells 
from two zygotes) by injecting cells of a selected cell line into host blastocysts 
(DeChiara et al, 1990). Targeted mutagensis of the IGF-II gene then results in small, 
but viable mice (DeChiara et al, 1991) as shown in Fig. 1.6. 
2 6 
Chapter I Introduction 
M 隱 
i M 
Fig. 1.6 Postnatal growth in igf-I and igf-II mutant mice. 
(A) A pair of 6-day-old and a pair of 2-month old littermates, wild-type (w and W) 
and igf-I (-/-) mutants (I and I) (Baker et al., 1993). (B) Example of 9-day-old 
wild-type and heterozygous littermates of igf-II mutants (DeChiara et aL, 1990). 
The experiments with the disruption of one IGF-II gene in mice clearly 
demonstrated the effects of parental-specific imprinting of IGF-II gene expression 
(DeChiara et al, 1991; Zhou and Bondy, 1992). Maternally derived IGF-II gene 
transcripts are normally undetected in mice except for transcripts localized to the 
choroid plexus. Transcription is noted from birth alleles in these tissues which are 
the only ones expressing IGF-II in normal adult animals (DeChiara et al, 1991). 
Chimeric animals generally demonstrate a dwarfed phenotype only when they inherit 
a paternal deletion of IGF-II (DeChiara et al, 1991). That is, animals that inherit the 
mutated IGF-II allele from the father, but not the mother, have growth retardation in 
utero (DeChiara et al, 1990), consistent with IGF-II being a regulator of fetal growth 
(DeChiara et al, 1990; Rosen et al, 1993). Growth inhibition begins before 
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embryonic day 16 and persists until birth. The affected mice have proportionate 
dwarfism (Deal and Guyda, 1983; DeChiara et al, 1991). The effect of the mutation 
is exerted only during the embryonic period. It is unknown whether the mutation 
affects the embryo directly, indirectly, or both, since there is also a proportionate 
reduction in the size of the placenta (DeChiara et al, 1990;DeChiara et al, 1991). 
Growth failure may thus be secondary to the reduction in placental size and/or the 
indirect result of impaired trophic functions of the placenta following the deletion of 
the IGF-II gene. Interestingly, DeChiara et al (1991) proposed this as a possibility, 
albeit unlikely, because the ratio of the weight of the placenta from affected animals to 
that from normal size animals is the same as the ratio of their body weights. 
However, the more logical explanation is that the absence of the IGF-II impairs 
proliferation in both the embryo and placenta. Thus, this murine model provides the 
best evidence for a physiological role of IGF-II in embryonic growth. 
1.1.6 Expression of recombinant IGF 
A major obstacle in IGF research, the scant availability of the pure peptides, 
has now being overcome with the advent of recombinant IGFs (rIGF). However, 
there are still difficulties in the expression. For rIGF-I, a glycosylated form of 
rhIGF-I was found in addition to the unglycosylated native form (Gellerfors et al, 
1989). 
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Expression of rIGF-II is apparently more cumbersome. For unknown 
reasons, it tends to be more denatured and insoluble in prokaryotic system, more 
difficult to renature and prone to proteolytic degradation. The expression of 
rhIGF-II was described in E. coli as a fusion protein (Hummel et al, 1989) and as a 
double-fusion protein (Hammarberg et al, 1989) for protection against proteolysis. 
1.2 Rationale and Objective 
In the past, studies of IGFs in human model have significant 
accomplishment both in the aspect of molecular biology and biochemistry. In fact, 
the largest, most diverse group of vertebrate animals is not represented by mammals 
but by fish. Almost all the biological functions present in mammals are represented 
by the incredible diversity of fish that may be contributed by the polyploidy. Their 
evolutionary adaptability to different environments and external fertilization make 
fish ideal for the studying the evolution of regulatory mechanisms in growth and 
development of vertebrates. The understanding of underlying mechanisms of 
growth and development in fish will undoubtedly contribute to knowledge of the basis 
physiology of vertebrates in general. To a further extent, some extant species that 
survived hundreds of millions of years of evolution allows comparative genetic 
approaches that are invaluable. Moreover, information on fish growth may prove to 
be valuable to aquaculture for efficient production to meet the need for fish products 
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by a continually growing human population. 
In order to examine the biochemistry and molecular biology of IGFs in fish, 
common carp {Cyprinus carpio) is chosen as the study model. The cyprinids 
constitue one of the largest families and are by far the largest group of cultured 
aquatic organisms. They are widely distributed in North America, Eurasia and 
Africa but are absent naturally from South America, Madagascar and Australia. The 
diversity of cyprinid species is at its greatest in China and in Southeast Asia but is 
lower in Africa and North America where there are nevertheless 36 genera and 280 
species. From the point of karyology, cyprinids generally possess 48-50 pairs of 
chromosomes but some species such as the common carp have sometimes more 
(Billard, 1999). Another important reason for choosing common carp is that it is a 
non-salmonid species. This diploid teleost allows comparsion of substitutions in 
IGF sequences and subtypes emerged that might occur during the teleost evolution. 
The interplay of IGFs with each other, with other hormones, with their 
binding proteins and receptors is apparently more complex than most of us imagined. 
Coming from separate genes, IGF-I and IGF-II can be readily distinguished on the 
basis of differences in nucleotide, predicted amino acid sequence, tissue mRNA levels, 
developmental mRNA levels, responsiveness to hormonal factors and serum peptide 
levels. Much greater attention has been devoted to IGF-I that modulates many of the 
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biologic effects of growth hormone and promotes growth during childhood 
(Daughaday and Rotwein, 1989). The exact biologic role of IGF-II and even of the 
enigmatic type 2 IGF receptor is cloaked in mystery. It should be a challenge to our 
inquiring minds. However, this view is in contrast to statements sometimes heard 
characterizing IGF-II as a functionless evolutionary relic. In my mind, nature is 
enigma in the underlying that living cells are self-regulating chemical engines, 
adjusted for maximum economy (Lehninger et al, 1993). 
In common carp, only one subtype of IGF-I and no IGF-II was found so far 
(Liang et al, 1996). Genomic Southern analysis performed on common carp 
demonstrated there would be more than one IGF gene in the genome of common carp. 
This phenomenon was investigated by a series of homologous RT-PCRs designed to 
amplify the full-length cDNA sequence of common carp IGF-II. The intro-exon 
junction would also be identified to elucidate the gene structure. 
Mammalian IGF mRNA levels vary dramatically with age and between 
tissues. In order to begin to understand the common carp organ system, a 
description of IGF levels in various tissues of both sexes and at different stages was 
undertaken by RNAse protection assays (RPAs). RPA provides a highly sensitive 
and specific quantitative method as an alternative to reverse transcription and 
polymerase chain reaction (RT-PCR) and Northern blot. 
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In mammals, it is clear that GH plays a role in regulating the levels of both 
IGF-I and IGF-II by the ends of gestation. GH clearly regulates IGF-I during the 
postnatal growth in mammals (Daughaday and Rotwein, 1989) and in fish (Duguay et 
al, 1994). However, its effect on IGF-II is controversial (Kim et al, 1993; Okuma 
and Kawashima, 1980). The regulators of IGF-II secretion in the fetus remain 
undefined. The enduring controversy happens in fish. The mIGF-II level shows 
GH-independence in the seabream model (Duguay et al, 1996) whereas it shows 
GH-ependency in the rainbow trout study (Shamblott, 1994). The GH-IGF axis in 
common carp was investigated by RPA. 
To verify that the isolated IGF-II clones contain an ORF coding the full 
amino acid sequences, the common carp IGF-II was translated in vitro and the protein 
size was as predicted. The IGF polypeptides were purified and the Western blot has 
been carried out. 
In summary, we would like to achieve a few goals in this study: (1) to isolate 
IGF-II cDNA in common carp and its gene structure; (2) to study the relative 
expression of IGF mRNAs in adult tissues, juvenile tissues and during larval 
development of common carp; (3) to study the GH regulation on IGF-I and IGF-II 
expression in common carp and to identify their difference in response; and (4) to 
obtain the biologically active recombinant common carp IGF-II protein. 
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Chapter II: Methodology 
2.1 Design of degenerate primers 
Fig 2.1 shows the strategy of the degenerate primer design from the 
heterologous amino acid sequences alignment of IGF-II from Tilapia (Chen et al, 
1997), Lates calcarifer fCollet et al, 1997), Oncorchynchus my kiss (Shamblott and 
Chen, 1992) and O. keta (Palamarchuk et al, 1997). The sequences of primers are: 
111: 5，一GARACSCTRTGYGGCGGRGA—3’ (degeneracy = 96); 
F1: 5'—TCGGCRGARACGCTRTGTGGRGG—3 ‘ (degeneracy = 16); 
F2: 5AAACCYGCCAAGTCMGARAGG—3‘ (degeneracy = 8); 
130: 5SYAGRGAGGTGGCHGASASGT—3‘ (degeneracy = 48); 
R3: 5CCTYTCKGACTTGGCRGGTTT—3‘ (degeneracy = 8); 
R4: 5,—CCGYTGRGCMGCCTTCCTCTG—3’ (degeneracy 二 8). 
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Fig. 2.1 Heterologous amino acid sequence alignment of (a) Tilapia (Chen et al, 
1997)，(b) Lates calcarifer (Collet et al” 1997)，(c) Oncorchynchus my kiss 
(Shamblott and Chen, 1992) and (d) Oncorhynchus keta (Palamarchuk et 
al., 1997) for the basis of the design of the degenerate primers. The 
non-identical amino acids were shown in light color while the identical amino 
acids are indicated as “-”. The B-, C-, A- and D- domain are embraced by 
rectangles. 
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2.2 Cloning 
2.2.1 DNA extraction from agarose gel 
One percent agarose gel was set by adding of 0.4 g agarose to 40 ml 1 x TAE 
buffer and was dissolved in a microwave oven. The agarose solution was cooled to 
60°C and ethidium bromide was added. The mixture was then poured into the gel tray 
with comb and allowed to cool and harden. The gel was immersed in 1 x TAE buffer. 
Five to twenty microlitre PCR products was loaded to the agarose gel with 6 x 
gel-loading buffer and run at 100 V. The gel was then photographed by UV 
illumination. 
The area of gel containing the DNA fragment was isolated using a clean, 
sharp blade. The gel extraction was then performed using Concert™ Matrix Gel 
Extraction kit (Gibco™) and the procedures as recommended by the supplier were 
followed. 
2.2.2 Linearization and dephosphorylation of plasmid DNA 
Plasmid vector (20 |Lig) was digested at 25°C with 60 units of Sma I in a 50 |ul 
reaction mixture containing 5 |li1 of 10 x reaction buffer and 0.5 BSA. The mixture 
was incubated overnight and resolved a 2 )li1 aliquot to a 0.9% agarose gel to verify its 
quality. After verification, 4 microlitre of calf intestinal alkaline phosphatase (CIAP) 
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was added and incubated at 37°C for 1 h. The digested vector was purified by adding 
200 |Lil phenol and 200 |ul chloroform. After the separation of 2 layers, the aqueous 
layer was extracted again with 200 jul of chloroform. Ethanol precipitation was then 
performed by adding 0.1 volume of 3M NaOAc and 2.5 volume of absolute EtOH to 
the aqueous layer that removed to a clean tube. The reaction mixture was stored 
at -20°C for 2 h and centrifuged at 14000 g for 30 min. The pellet was washed with 500 
fil of 70% EtOH, then vortexed and centrifuged again at 14000 g for 5 min. The 
supernatant was aspirated off and the pellet was eluted in 120 jul dH20. 
2.2.3 Blunt-end ligation of amplicon with linearized plasmid 
The PGR products were pooled and resolved on a agarose gel. The DNA 
bands were excised from agarose and extracted as stated in section 2.2.1. The 
recovered amplicon was then processed for cloning that including polishing and 
kinasing by adding 20 jul 5 x forward reaction buffer, 1 ]i\ 0.1 mM ATP, 2 |ul 10 mM 
dNTP, 1 \i\ Klenow DNA polymerase and T4 kinase and incubated at 37°C for 1 h. The 
phosphorylated DNA was purified from the excess primers, enzymes and salt with 
Concert™ Rapid PGR Purification System (Gibco™) or QIAquick PGR Purification 
kit (QiagenTM). The protocols as recommended by the supplier were followed. The 
vector (10 ng) and processed amplicon was mixed together in a ratio of 1:3 with 2 jitl 10 
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X ligation buffer, 1 |LI1 T4 DNA ligase (PromegaTM, 3U/ ml) and dHzO to a final volume 
of 20 )Lil and incubated at 15°C overnight. After overnight ligation, the sample was 
ready for the transformation in competent bacterial cells. Alternatively, ligation was 
also performed with Ready to Go™ kit (Amersham Pharmacia Biotech™), where 
contents for ligation except DNA were already in the ligation tube. 
2.2.4 T/A ligation of amplicon with linearized plasmid 
The amplicon was modified by adding overhang A. Twenty microliter 
amplicon was mixed with 3 |ll1 10 x PGR buffer, 3 |ul 25mM MgCb, 1.5 jul 10 mM dATP, 
1 |Lil Taq and then incubated at 70°C for 30 min. The tailed amplicon purified with 
ConcertTM Rapid PGR Purification System or QIAquick PGR purification kit. The 
purified DNA was ligated into pGem-T Easy vector (PromegaTM) using the method as 
described in section 2.2.3. 
2.2. 5 Sticky end ligation of foreign DNA with linearized plasmid 
A parallel restriction enzyme digestion was done with approximately 2 \xg of 
vector DNA (pBS SK+) and 200 ng to 1 \ig insert DNA either from PGR or plasmid. To 
the reaction mixture, 3 jul of 10 x corresponding buffer and (fflbO was added up to a 
final volume of 30 \i\. It was incubated at 37°C overnight. Both linearised vector and 
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insert was resolved in 1% agarose gel and excised afterwards as stated in section 2.2.1. 
The ligation was then carried out as stated in section 2.2.3. 
2.2.6 Preparation of competent of E. coli strain DH5a cells 
Single colony of E. coli strain DH5a was isolated from the stock that stored 
at -80°C and inoculated with 3ml Lbroth (Lauria-Bertani). The bacteria was grown 
overnight at 37°C in a shaking incubator with 250 rpm. Approximately 1ml of 
overnight bacterial culture was used to inoculate 200ml Lbroth. When the bacterial cell 
culture was grown to OD6oo=0.3 to 0.5, it was divided into two equal portions and 
transferred to sterile 250ml polypropylene bottles respectively. The bacterial cells were 
ice-chilled for 5 min, collected by centrifugation at 6000 g for 10 min at 4°C and the 
cell pellet in each bottle was gently suspended with 20 ml ice-cold Ca/glycerol buffer 
twice. The cells were incubated in Ca/glycerol buffer on ice for 30 min. The cells were 
collected by centrifugation at 6000 g for 5 min at 4°C and gently resuspended with 5ml 
Ca/glycerol buffer. Hundred micro litre aliquots of competent cells were dispensed into 
the pre-chilled microcentrifuge tubes and stored at —80°C until use. 
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2.2.7 Transformation of plasmid vector into competent cells (heat-shock/ 
electroporation) 
To transform the competent cells by the CaCb method, a ligation mixture was 
added to 100 ]i\ of competent cells and the mixture was incubated on ice for 30 min to 
allow the attachment of plasmid DNA with the surface the competent cells. The cells 
were then subjected to heat-shock by incubation at 42°C for 2 min and then ice-chilled 
for 5 min for stabilization. Nine hundred microlitre Lbroth was added on flame and 
then the cells were allowed to grow for 45 min at 37°C. The mixture of 40 jul 0.1 M 
IPTG (isopropylthio-(3-D-galactoside) and 40 \i\ of 20mg/ ml X-gal 
(5-bromo-4-chloro-3-indolyl-(3-D-galactoside) were spread on the Lbroth agar plate. 
The competent cells were pelleted by a table-top centrifuge and was then resuspended 
in about 300 and spread on Lbroth agar plate with the corresponding antibiotic. 
To transform the competent cells by electroporation, the electro-competent 
cells that thaw on ice were transferred into an ice-chilled EppendorFM electroporation 
cuvette. A ligation mixture or plasmid DNA was added into it. The cuvette with the 
mixture was inserted into the tray of the Electroporator 2410 (EppendorFM). The 
electric pulse was applied at a voltage of 2.5 kV. After the electric pulse, 1 ml of Lbroth 
medium was added. The mixture was transferred into a microcentrifuge tube and the 
cells were allowed to grow for 45 min at 37°C. The competent cells were spread on the 
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Lbroth agar plate as mentioned above. 
2.2.8 Spread single colony, PGR check clone and inoculation 
The white colonies were isolated out from the blue ones that were self-ligated 
clones onto a new Lbroth agar plate and were allowed to grow at 37°C overnight. 
Polymerase chain reaction (PCR) was then performed to screen the clones. A part of 
each single colony was added with toothpick to the reaction mixture of 0.5 |ul reverse 
gene specific primer, 0.5 |li1 forward gene specific primer, 2.5 jjJl 10 x PCR buffer, 0.75 
\i\ 50 mM MgCb, 0.5 |LI1 dNTP, 0.25 |LI1 Tag and cfflbO in a 0.2 ml microcentrifuge tube. 
The reaction mix was denatured at 94°C for 2 min and subjected to 25 cycles of: 1 min 
denaturation at 94°C, 30s primer annealing (depending on the predicted Tm of the 
oligonucleotide primers and the desired specificity) at 55°C, 2 min polymerization 
(depending on the length of predicted amplicon) at 72°C. The reaction was then held at 
72°C for 10 min and kept at 4°C. Fifteen microliter of the amplicon was resolved on a 
1% agarose gel. The clones would be selected out if the size of the amplicon was as 
expected. A single colony of bacteria after verification with PCR was transferred into 
approximately 3 ml of Lbroth medium with 3 |ul ampicillin (lOmg/fj.1) in a snap-capped 
15 ml culture tube and harvested at 37°C with shaking overnight. 
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2.2.9 Small scale alkali preparation of plasmid DNA (Concert^^ Rapid 
Plasmid Miniprep System) 
Small-scale plasmid DNA preparations were done to facilitate the initial 
verification of large numbers of recombinant plasmid clones. Approximately 3 ml of 
bacterial overnight culture was pelleted at 12000 g for 30 s to remove all medium. The 
protocol was as recommended by the supplier was followed. 
2.2.10 Large scale preparation of plasmid DNA 
A single colony from a freshly streaked selective plate was picked and 
inoculated in a starter culture of 5 ml Lbroth containing the appropriate antibiotic. The 
culture was incubated overnight at 37°C. The starter culture was diluted into 100 ml 
selective Lbroth medium in a 1/500 ratio. The diluted culture further incubated at 37°C 
overnight. The large scale plasmid preparation were done with the QIAfilter'^^ Plasmid 
Maxi Preparation Kit (Qiagen™) by following the recommended protocol. 
2.2.11 Nucleotide sequencing 
2.2.11.1 Manual sequencing 
Nucleotide sequences were determined in both directions by the alkaline 
denaturation and dideoxynucleotide chain-termination method using a kit from 
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Amersham Pharmacia Biotech™. Double stranded DNA templates were denatured by 
incubation of 1.5-2 昭 DNA in 2 M NaOH/ 0.1 M EDTA, pH 8.0 for 5 min at 6 5 � C in a 
total volume of 40 jul. Template DNA was then neutralized and precipitated by the 
addition of 7 fil 3 M NaOAc, pH 7.8, and 4 |li1 of dl^bO. 120 |Ltl of absolute EtOH. The 
reaction was precipitated for 15 min at —80°C, spun for 15 min at 14000 g and then 
washed with 200 \i\ of 70% EtOH. The pellet was vacuum dried by Speed-Vac for 5 
min at 65°C, and further resuspended in 10 |ll1 dH^O, 2 jliI annealing buffer and 2 jul 
oligonucleotide primer (15-30 mg/ml). Primer annealing was carried out at 65°C for 5 
min then 37°C for 10 min then cooled slowly to room temperature. 
To the annealing template, 1 )li1 [a-^^S]dATP, 3 )li1 labeling mix-dATP, 2 jul T7 
DNA polymerase diluted 1:4 in enzyme dilution buffer were added sequentially. This 
labeling reaction was incubated at room temperature for 5 min. To each of the 4 labeled 
microcentrifuge tubes, containing 2.5 of G, C, A and T termination mixes, 4.5 jul 
labeling reaction were added and incubated at 37°C for 5 min. The reaction was 
terminated by the addition of 5 ml stop solution and stored at -20°C. 
The glass of the manual sequencing set was washed with washing detergent 
and then 70% EtOH. A thin layer of repellent was coated on the glass surface and the 
gel tank was set up with the fixing of anti-leaking paper. A 6% acrylamide casting 
sealing gel was set at the downstream by mixing 6 ml Solution A (20% acrylamide), 14 
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ml Solution B (Urea mix), 250 )ll1 of 10 % APS (ammonium persulfate) and 100 jul 
TEMED. An 8% acrylamide denaturing gel was then cast overhead by mixing 20 ml 
Solution A, 30 ml Solution B, 0.4 ml of 10% APS and 50 |li1 TEMED. The gel was 
allowed to set at room temperature overnight. 
Sequencing reactions were heated to 80°C for 5 min prior to loading on a 8% 
acrylamide denaturing gel cast in 1 x TBE that had been pre-run at 48 Watt (W) until the 
temperature of the gel reached 45-50°C. The wells were rinsed beforehand to remove 
urea. The reactions were run for 3 h at 48 W then loaded a second time and run for an 
additional 4 h at 48 W. Sequencing gel was placed on a sheet of 3 mm Whatmann paper 
and dried for 1.5 h at 80°C under vacuum. Dried sequencing gel was then exposed to 
Kodak BioMaxTM MR autoradiography film for 1-2 days and developed. The 
nucleotide sequences were read manually and analyzed with the computer software 
(DNAsis). 
2.2.11.2 PCR sequencing 
PGR sequencing was performed with the ABI Prism dRhodamine Terminator 
Cycle Sequencing Ready Reaction Kit. The protocol was recommended by the supplier 
(Perkin Elemer Applied Biosystems™) using PCR. To amplify the DNA templates, 50 
ng per 1-kb double-stranded plasmid DNA was vacuum-dried and adjusted to 4.4 )liI 
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with dH20. To the template 1.6 pmol oligonucleotide primer, 4.4 jul Terminator Ready 
Reaction Mix and dHsO were added to a final volume of 10 jllI. The reaction mix was 
then subjected to 25 cycles of: 10 s denaturation at 96°C, 5 s primer annealing at 50°C, 
4 min polymerization at 60°C. 
The reaction mixture was then held at 4°C. To stop the reaction, 1 |ul of CIAP 
was added and incubated at 37°C for 30 min. The reaction mixture was transferred into 
a microcentrifuge tube, 50 |LI1 of absolute ethanol and 3 |LL1 of 3M sodium acetate (pH 4.6) 
was added to remove the unincorporated dyes. The tubes were stored at —20°C 
overnight to precipitate the PGR products which were recovered by centrifugation at 
14000 g for 30 min at 4°C. The supernatant was aspirated away carefully and the pellet 
was further rinsed with 250 \Ji\ of 70% ethanol. After the centrifugation at 14000 g for 
15 min at 4°C of the microcentrifuge tube, the supernatant was discarded. The pellet 
was vacuum-dried for 5 min at 65°C and resuspended in 12 jul of template suppression 
reagent (TSR) with vortex. The reaction mix was denatured at 95°C for 2 min and then 
chilled on ice. The reaction mix was spun, transferred to the appropriate tube that 
suited the ABI PRISM 310 automatic sequencer, and then injected into the machine. If 
the reaction mix was not ready to inject right away, it could be stored at 4°C wrapped in 
aluminum foil wrap to avoid exposure to light. 
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2.3 Northern blot 
The RNA was extracted as described in section 2.7.2 and the mRNA was then 
isolated as described in section 2.6. Five jug mRNA was undergone formaldehyde 
agarose gel electrophoresis as described in section 2.7.3. The gel was photographed by 
the UV transilluminator with a UV-sensitive ruler after rinsing with dHsO for about 15 
min. Unidirectional capillary transfer or vacuum transfer was then carried out. 
For the unidirectional capillary transfer, the tray was filled with transfer 
buffer 10 x SSC and a platform was covered with a wick that was made from 3 sheets of 
Whatman 3 mm filter paper which were saturated with transfer buffer. The gel was 
placed on the wick in a way to avoid trapping air bubbles beneath it. It was surrounded 
with cling film to prevent the transfer buffer being absorbed directly into the paper 
towels above. A sheet of Hybond-N membrane was cut to the exact size of the gel and 
placed on top of it. Bubbles should be squeezed out using a glass rod or pipette. Three 
sheets of Whatmann 3 mm filter paper that wetted with transfer buffer were placed on 
top of Hybond-N membrane. A stack of absorbent paper towels was placed on top of it 
and then a 0.75-1 kg weight. The transfer was allowed to proceed for 12-16 h. After 
blotting, the apparatus was dismantled carefully before removing the gel. The 
membrane was marked with pencil to allow later identification of tracks, washed with 2 
X SSC, air-dried, UV cross-linked for 4 min and stored at 4°C in a plastic bag. 
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For the vacuum transfer, a Hybond-N membrane was placed on the blotter 
carefully. A plastic blocker was overlaid and then the gel. A layer of transfer buffer 
was poured on the top of the gel. The vacuum pump was turned on and the pressure 
was kept at 50 mbar for 1.5 h. The orientation of the gel was marked on the membrane 
as the capillary transfer that mentioned above. The membrane was washed with 2 x 
SSC, air-dried, UV cross-linked in an UV-cross-linker for 4 min and stored at 4°C in a 
plastic bag. 
2.4 Preparation of radio-labeled probe and hybridization of radio-labeled probe 
to nylon immobilized nucleic acid 
The nylon membrane was prehybridized in a plastic dish containing 
approximately 50 ml hybridization solution for 1 h at 65°C with denatured calf thymus 
DNA by heating at 99°C for 5 min and then ice-chilled. The hybridization solution was 
mixed to a final concentration of 5 x SSC, 5 x Denhardt's solution and 0.5% SDS. 
Probe radiolabeling can be carried out by Nick translation (Amersham Pharmacia 
Biotech™) or random labeling (Ready-to-goTM). For nick translation, 50 ng DNA 
(usually PCR product), 10)li1 nucleotide mix, 5 \i\ dCTP and 5 )ul enzyme mix were 
incubated at 14°C for 1-2 hr; whereas for random labeling, a tube of Reaction Mix was 
reconstituted by adding 20 \i\ dHsO and incubated on ice for 10 min. Less than 25 jul 
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denatured DNA, 50)j.Ci [a-^^P] dCTP and dHsO were added to a final volume of 50 juI. 
The reaction mixture was mixed by gently pipetting up and down several times. 
Bubbles were removed by a pulse centrifugation. The reaction was incubated at 37°C 
for 30 min. 
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The unincorporated dye and excess dCTP was removed by S200 HRcolumn 
(Amersham Pharmacia Biotech™). The resin in the column was resuspended by 
vigorous vortex. The cap of the column was loosened a quarter turn and the bottom 
closure was snapped off. The column was placed in a 1.5 ml microcentrifuge and 
pre-spun at 735 g for 1 min to remove the TE buffer. The column was then placed in a 
new microcentrifuge tube. The sample was loaded onto center of the wet resin. The 
whole setup was spun at 735 g for 3 min. The cpm ratio of the column and elute should 
be 1:2 or nearly the same. The radiolabeled probe was denatured at 99°C for 5 min and 
ice-chilled. The probe was pipetted into the hybridization solution that with the 
membrane at 4 corners. The solution was placed at 65°C overnight in a slowly shaking 
incubator for the hybridization. 
Step up stringency washes were carried out. The membrane was washed with 
2 X SSC and 0.1% SDS at room temperature for 10 min twice. For higher stringency, 2 
X 15 min wash with 1 x SSC and 0.1% SDS and then 0.1 x SSC and 0.1% SDS at 6 5 � C 
was carried out. The radioactivity remained on the membrane was monitored 
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throughout the process. Membrane was allowed to air dry incompletely, wrapped in 
plastic wrap, mounted on the X-ray film and then exposed to Kodak autoradioagraph 
film with an intensifier screen. 
2.5 RACE 
Rapid Amplification of cDNA Ends (RACE) is a procedure for amplification 
of nucleic acid sequences from a total RNA or messenger RNA template between a 
known internal sequence and unknown sequences at either the 3' or the 5' -end of the 
mRNA. This methodology of amplification with single-sided specificity has been 
described by others as "one-sided" PCR or "anchored" PCR (Humbel, 1990). 
3' RACE takes advantage of the natural poly (A) tail in mRNA as a generic 
priming site for PCR amplification. In this procedure, mRNAs are converted into 
cDNA using reverse transcriptase (RT) and an oligo-dT adapter primer. Specific cDNA 
is then directly amplified by PCR using a gene-specific primer (GSP) that anneals to a 
region of known exon sequences and an adapter primer that targets the poly (A) tail 
region. This permits the capture of unknown 3'-mRNA sequences that lie between the 
exon and the poly (A) tail. 
The 5’ RACE system comprises a set of processes including the synthesis of 
first strand cDNA, purification of first strand products, homopolymeric tailing and 
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preparation of target cDNA for subsequent amplification by PGR. 
First strand cDNA was synthesized from total RNA using a GSP and 
superscript丁M II. After first strand cDNA synthesis, the original RNA template was 
removed by treatment with the RNase mix (mixture of RNase H, which was specific for 
RNA:DNA heteroduplex molecules, and RNase Tl) . Unincorporated dNTPs, GSP and 
proteins were separated from the cDNA. A homopolymeric tail was then added to the 
3'end of the cDNA using TdT and dCTR Since the tailing reaction was performed in a 
PCR-compatible buffer, the entire contents of the reaction might be directly amplified 
by PGR without intermediate organic extractions, ethanol precipitations, or dilutions. 
PGR amplification was accomplished using Taq DNA polymerase, a nested GSP that 
annealed to a site located within the cDNA molecule, and a novel 
deoxyinosine-containing anchor primer. 
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Fig. 2.2 Diagrammatic representation of the experimental approach for 
isolation of the complete cDNA sequence by RACE. (Chenchick et al” 
1995) 
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2.5.1 Design of gene-specific primer 
Five GSPs were designed for the 3'RACE and 5, RACE. 
5 ’ ^ 3, 
Signal pept ide B l l J U X M P B E 
G S P 6 F — G S P 7 F — 
< G S P 8R 
< ~ G S P 9R 
G S P lOF ~ > 
Fig 2.3 Diagrammatic representation of gene specific primers that designed 
for RACE. 
Arrows indicate the approximate beginning and end of the nucleotide 
sequences determined, as well as their orientation. The striped region 
represents the cDNA sequence that obtained from the degenerate primers. 
2.5.2 First strand cDNA synthesis 
The first strand cDNA synthesized would be used in the PGR and 3’ RACE. 
Approximately 1 t^g tissue RNA or poly (A) enriched RNA was added to a 
nuclease-free microcentrifuge tube with Ijul of 500 jug/ml oligo (dT) 12-18, heated to 
70°C for 10 min and quick chilled on ice. The content of the tube was collected by brief 
centrifugation and 4 )ll1 of 5 X first strand buffer, 2 of 0.1 M DTT, 1 |li1 of lOmM 
dNTP was added. The reaction mixture was mixed by gently vortexing and collected 
by brief centrifugation. The tube was placed at 42°C for 2 min to equilibrate the 
temperature. One }i\ of 200units/jLil of Superscript™ II (Gibco™) was added and 
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incubated at 42°C for 1 h. The first strand cDNA synthesized was stored at -20°C. 
In the preparation for 5' RACE, approximately 1 }Ag tissue RNA was added to 
a nuclease-free 0.2 ml thin-walled PGR tube with 2.5 pmol GSP and DEPC-treated 
water that was sufficient for a final volume of 15.5 )LL1, heated to 70°C for 10 min to 
denature RNA and quick chilled on ice. The contents of the tube was collected by brief 
centrifugation and 2.5 of 10 X PGR buffer, 2.5 i^l of 25mM MgCb, 2.5 |Ltl of 0.1 M 
DTT, 1 )LL1 of 1 OmM dNTP was added to a final volume of 24 |LIL The reaction mixture 
was mixed by gently vortexing and collected by brief centrifugation. The tube was 
placed at 42°C for 1 min to equilibrate the temperature. One fil of 200units/jLLl of 
Superscript™ n RT (Gibco™) was added and incubated at 4 2 � C for 50 min. The 
reaction mixture was then incubated at 70°C for 15 min to terminate the reaction. It 
was briefly centrifuged, placed at 37°C and 1 jul of RNase mix was gently mixed and 
incubated at 37°C for 30 min. The first strand cDNA synthesized was stored at —20°C. 
2.5.3 TdT tailing of cDNA 
Variable amounts of purified cDNA might be used in the TdT-tailing reaction. 
In a 0.2 ml thin-walled PGR tube, 6.5 i^l of DEPC-treated water, 5 of 5 x tailing 
buffer, 2.5 \i\ of 2mM dCTP was added to 10 i^l of purified cDNA. The reaction 
mixture was incubated at 94°C for 2 min and chilled on ice. The contents were 
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collected by brief centrifugation, 1 |LL1 ofTdT was added, mixed gently and incubated at 
3 7 � C for 10 min. The TdT was then inactivated at 65�C for 10 min and then kept at 
4 � C . 
2.6 Poly-A tract extraction 
PolyATtract® Systems was used for small-scale mRNA isolation and the 
protocol as recommended by the supplier were followed. The mRNA was finally 
eluted in 250ml RNase-free water and then spectrophotometrically quantified. The 
mRNA was reverse-transcripted to synthesis the first strand cDNA immediately. 
2.7 Tissue distribution 
2.7.1 Tissue preparation 
Juvenile carps of about 6 cm were kindly provided by the Agriculture and 
fisheries Department in Hong Kong and some were collected from the fish pond in Gao 
Ming of Mainland China. Adult carps were bought from the local market. Carps were 
anesthetized and then rapidly dissected. Tissues were wrapped in the marked tin foil or 
put into the marked Falcon tubes and immediately submerged in liquid nitrogen, then 
stored at -80°C until required. 
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2.7.2 Total RNA extraction 
Tissues of juvenile carps were cracked with syringe and descending size of 
needles. Tissues of adult carps were homogenized with a Polytron® PT3100 for 1 min. 
The probe of Polytron® PT3100 was autoclaved and cleaned with DEPC treated water 
before used. Tissue mass ranging from O.lg to 0.5g was homogenized with TRIzol 
Reagent solution in the ratio of O.lg to 1 ml TRIzol Reagent. The homogenate was 
aliquoted into 1.5-ml microcentrifuge tube with 1 ml each. 0.2 ml chloroform was 
added and mixed vigorously for 15 seconds. The homogenate was stood on ice for 2 
min and then centrifuged at 12000 g for 15 min at 4°C. The aqueous supernatant was 
transferred into a new microcentrifuge tube, an equal volume of isopropanol was added, 
vortex mixed and then centrifuged at 12000 g for 10 min at 4°C. The RNA pellet was 
washed with 1 ml of 75% ethanol and then centrifuged at 12000 g for 10 min at 4°C. 
The RNA pellet was allowed to dry on ice, resuspended in DEPC-treated water, 
spectrophotometrically quantified and then analyzed on a 1% formaldehyde gel to 
verify the qualification and quantification. 
2.7.3 Formaldehyde agarose gel electrophoresis of RNA 
The isolated total RNA samples were electrophoresed to check their 
integrities. One gram of agarose was added to 88.2 ml dH20 and was boiled in a 
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microwave oven. The agarose was cooled to 60°C and then 10ml lOX MOPS and 1.8 
ml 37% formaldehyde was added, mixed, pored into the gel tray with comb and 
allowed to cool and harden. The gel was immersed in IX MOPS gel-running buffer. 
The mixture of 5 |Lig total RNA and 5 |LI1 stop solution was incubated at 65°C for 5 min 
and then ice-chilled. The samples were loaded and run at 60V for 2 hours. The gel was 
then photographed under UV illumination. 
2.8 Ribonuclease protection assay 
The ribonuclease protection assay (RPA) is a method for the quantification of 
specific mRNA levels. RPA method was chosen to differentiate the expression level of 
IGFs as it is 10-20 times more sensitive than Northern blot or RNA dot blot. In addition, 
RPA can be made absolutely specific to eliminate cross-reactivity. Any sequence 
disparity between the radio-labeled cRNA probe and the target mRNA would be 
attacked by RNAse T2, leaving smaller than expected protected fragments. Therefore, 
only 100% homologous probe that targeted over 100 bp region of the sequence would 
be used. 
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2.8.1 Antisense probe generation 
Probes was prepared by blunt-end cloning of PCR generated DNA into the 
Sma I restriction site of pBluescript SK+ vector. The probe of IGF-I and IGF-II coded 
for B-, C-, A- and D-domain respectively. The plasmid DNA was linearized by 
digestion with the restriction enzymes BamHI and Hind III for Ty and T3 RNA 
polymerase to generate the anti-sense RNA probe respectively. Linearized plasmid 
DNA was then ethanol precipitated with 3 M NaOAc and absolute EtOH, washed in 
70% EtOH, dried and resuspended in dH20 to a concentration about 0.5jLig/|LiL 
Antisense cRNA synthesis reaction was carried out by adding 5|LiCi [a- P 
UTP in a microcentrifuge tube that contains 0.5 jug linearized plasmid DNA, 1 jul 10 X 
transcription buffer, 2 rNTP-U (lOmM rGTP, CTP, ATP), 1 i^l T3 RNA polymerase 
with ribonuclease inhibitor. The reaction mixture was incubated at 37°C for 30 min. 
The template DNA was removed by the addition of 1 RNAse-free DNAse I (Ambion, 
2 U/|Lil). The reaction was mixed by flicking and brief centrifugation and then 
incubated at 37°C for 15 min. The reaction was stopped by the addition of Ijul 0.5 M 
EDTA and stored at -20°C. 
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IGF-II 
I G F - I G T A C C A T G C G C T G T C T C T C G T G C A C C C A C A C C C T C T C A C T G G T G C T G T G C G T C C 
s i g n a l p e p t i d e 
IGF-II ACGHTgTGCGGHcgG 
IGF-I T C G C G T T G A C T C C C G C G A C A C T G G A G G C G G G G C C G G A G A C G G T G T G C G G G G ^ G 
I I 
IGF-II A G C T G G T H G A C G C G C T | C A G T T T G T G T G T G G A G A C A G 0 G G H T T F F L T A T T T C A G R A 
IGF-I A G C T B G T S G A C S C G C T B C A G T T T G T G T G T G G A G A C A G B G G H T T H T A T T T C A G H 
B - d o m a i n 
IGF-II gACCAAC^G^^^GGj^EAG^^TOGACGHTCHCAgAABCGTGGgATTGTGG 
IGF-1 B A C C A A C B B G B M B B G G B B A G B B ^ G A C G B T C | C A G A A G C G T G G G A T T G T G G 
I I C - d o m a i n | | 
IGF-工：T A|G A|T GHT GHT T T^AgAGgT G TSAHC T^gMC^jc T^GA^gG TAHT GHG C B 
IGF-1 A 0 G A | T G G T G G T T T G A G A G G T G T G A G C T B H B C B I C T B G A S B G T A B T GGG C B B 
A - d o m a i n 丨 | 
I G F - I B B S T A A A B C C S G B C A A B ^ T C ^ H G A I ^ M E B 
D - d o m a i n 丨 | E - d o m a i n 
Fig. 2.4 Nucleotide sequence alignment of common carp IGF-I and IGF-II 
cDNA. 
Gaps are indicated by hyphens. The non-identical nucleotides are shown 
in black boxes. The signal peptide, B-, C-, A-, D- and E-domains are 
indicated below and the beginning of each domain are indicated by “ | ”. 
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2.8.2 Preparation of the sample RNA 
The total RNA was extracted from various tissues as stated in section 2.7.1 
and 2.7.2. The RNA quantity was determined by spectrophotometry at the wavelength 
of 260 nm by adding 4 ]i\ of RNA sample to 996 jul dHzO. Ten times of the reading 
would be the amount of RNA in )Lig/|Lil. The quality of RNA was determined by the 
ratio of wavelength at 260 nm to 280nm. The ratio of pure RNA would be 
approximately 2. Five |Lig total RNA was fractionated by 1% formaldehyde agarose gel 
as stated in section 2.7.3. The gel was then photographed by UV illumination and 
digitized by the molecular imager. 
2.8.3 Hybridization 
The hybridization reactions were carried out by the co-ethanol precipitation of 
sample RNAs with the anti-sense cRNA, in the addition of adjusting the final NH4OAC 
concentration to 0.5 M and adding 2.5 volumes of EtOH and then placed at —20°C for 
45 min. The sample was normalized to 50 jug with the yeast RNA when probing less 
than 50 jug of sample RNA. The control tube was set up by precipitating 50 jug yeast 
total RNA with the same amount of labeled probe. 
The probe and sample RNA was pellet for 15 min at 20000 g in 4°C 
microcentrifuge. The EtOH supernatant was carefully removed from each tube and the 
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samples was allowed to dry for 10 min at room temperature. Five jul of 95°C pre-heated 
HybSpeed Hybridization buffer was added to each pellet and the tubes were put 
immediately in a 95°C heating block. Each sample was vortexed thoroughly for 15 min 
and returned to the 95°C bath twice until all the pellets were completely dissolved. 
Attention was paid in keeping the samples as close to 95°C as possible because RNA 
was not soluble in the HybSpeed Hybridization buffer at temperatures below 65°C that 
might diminish the sensitivity of the HybSpeed System. All tubes were heated at 95°C 
for 2-3 min. Tubes was submerged in 69°C water bath for 10 min to permit 
hybridization of the probe and complementary mRNA in the sample RNA. The 
transfer of the tubes from 95°C bath to 69°C incubation should take no more than 30 s. 
2.8.4 RNase digestion of hybridized probe and sample RNA 
The working dilutions of RNase A/Tl (1:100) was prepared in HybSpeed 
RNase digestion buffer. RNase A/Tl should be vortexed, microcentrifuged briefly 
before use and kept at room temperature until use. Seventy-five fil of diluted RNase 
solution was added to all experimental tubes and no microcentrifugation was required. 
Tubes were incubated at 37°C with re-vortexing after 15 min. Precipitation was then 
carried out by the addition of 75 \i\ HybSpeed inactivation/precipitation mix to each 
tube. After brief vortexing, tubes were transferred to —20°C freezer for 45 min. 
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2.8.5 Preparation of radioactive marker 
The radioactive marker was prepared by the addition of 14 jLil DEPC water, 1 
i^l forward reaction buffer (Gibco™), 10 juCi dCTP to 1 i^l of DNA molecular 
weight marker VI. The reaction mixture was incubated at room temperature for 20 min 
and then 2 \i\ of 2.5 mM dNTP was added. After further incubation at room 
temperature for 5 min, the reaction was stopped by adding 1 |Ltl of 0.5 M EDTA. It was 
diluted with 400 |LI1 TE buffer and stored at —20°C. 
2.8.6 Separation and detection of protected fragments 
An 8% native polyacrylamide gel was prepared for separation of protected 
fragments of the expected size by mixing 8 ml of 30% acrylamide (polyacrylamide: 
bisacrylamide = 30: 8), 6 ml of 5 x TBE, 15 ml dHsO, 190 i^l APS and 25 i^l TEMED. 
Tubes were removed from the freezer and spun for 15 min at 20000 g in 4°C 
microcentrifuge. All supernatant was removed carefully from each tube as the residual 
supernatant would cause aberrant migration of bands in gel. Samples were resolved by 
loading on the polyacrylamide gel in 1 x TBE buffer. The gel was run at 150 V for 4 h 
with radioactive marker until the bromophenol blue band reached over 3/4 of the gel. 
The gel was then transferred to 3 mm Whatmann paper, wrapped in plastic wrap and 
transferred to the gel dryer for 45 min at 80°C that precluded the diffusion of bands. 
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The gel was placed in the molecular imager for autoradiographic analysis. 
2.8.7 Data processing and statistical analysis 
The radioactive signal was detected by the Molecular imager (Bio-Rad™ 
GS-505) which is composed of the image scanner, eraser and loading dock. The first 
step was the insertion of the imaging screen into the eraser to erase the background 
signal for at least 10 min. The screen cassette would not expose to any light afterwards. 
The polyacrylamide gel with the protected fragments was fixed on the loading dock by 
plastic tape and then covered with a sheet of Screen-Guard film overhead. The imaging 
screen was placed into the loading dock with the phosphor side facing the gel and the 
whole apparatus was locked. The imaging screen was then transferred to the image 
scanner from the loading dock after appropriate exposure time. The screen cassette was 
inserted into the scanner and the signal was digitized by the Molecular Analyst 
software. 
A constant area of each protected band was isolated out for comparison. The 
bands were normalized with the 18S of the RNA respectively. Student t-test was 
carried out by Sigma plot software. 
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2.9 Injection o f G H 
Juvenile common carp sized 6-8 cm long were raised in tanks under natural 
photoperiod and ambient water temperature at the fish culture room of the 
Biochemistry Department in CUHK. Fish were fed daily and starved for 15 days prior 
to the intraperitoneal (i.p.) injection. Fish were anaesthetized with 70% EtOH and 
given i.p. injection of recombinant porcine GH (BresGen™) at different concentrations 
in a volume of 100 ]i\ PBS. After 12 h, tissues were collected from 4 GH-treated and 4 
control fish, flash-frozen in liquid nitrogen, and stored at —70°C. Total RNA was then 
extracted and the IGFs mRNA levels were assayed by RPA. 
2.10 Recombinant protein expression 
2.10.1 Plasmid construction 
Amplicons was obtained by PCR (30 cycles, 1 min at 94�C, 30 s at 58°C, 1 
min at 72°C) with the engineered restriction enzyme sites (BamHI/ PstI) (Fig 5.1). For 
plasmid constructions, restriction fragments were purified from agarose gels and 
ligated with BamHI/ PstI digested pRSET A as mentioned in section 2.2.1 and 2.2.5. 
The ligation mix was then transformed into CaCb-treated BL21(DE3) or C41(DE3) 
cells as mentioned in section 2.2.7. The transformants were then cultured overnight at 
30°C with 1/1000 volume ampicillin as starter culture. 
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2.10.2 Expression 
The starter culture (1/50 volume) was added into freshly prepared culture 
medium with 1/2000 volume ampicillin and incubated at 37°C until the optimal 
absorbance at 600nm (0.4-1.0) was reached. IPTG was added at a final concentration 
of ImM to induce growth except control. The culture was incubated for 5 more h at 
3 7 � C and then stored at 4 � C . 
2.11 Resolution of proteins on SDS-PAGE 
The cell was collected by centrifugation at 4000 g for 10 min and the pellet 
was then suspended in 100 |LL1 TBS. To the 10 samples was added 10 |ul 2 x sample 
buffer, and the mixture was heated to 99°C for 3 min. The samples were then loaded 
onto 20% SDS-PAGE or Tricine SDS-PAGE and run at 30 mA constant current 
(SDS-PAGE) or run at 30 V until reaching separating gel and then increased to 100 V 
(Tricine SDS-PAGE). The gel was run until the desired resolution was achieved as 
judged by the resolution of pre-stained molecular weight marker (GIBCOBRL™ low 
molecular weight marker). The acrylamide gel was then stained in Coomassie blue 
stain and destained in destaining solution. 
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2.12 Purification 
The small scale ( � 3 ml) purification of recombinant proteins was carried out 
with the XpressTM Protein Purification System by following the protocol as 
recommended under denaturing condition. The cell lysate obtained by sonification was 
separated into pellet portion and supernatant portion by centrifugation at 3000 g for 15 
min. Resolution of protein was carried out again as described in section 2.11. 
2.13 Western transfer 
Semi-transfer using the PhastSystem (Amersham Pharmacia Biotech™) was 
employed for the Western Blot from SDS-PAGE gel. The PVDF membrane was wetted 
in 100 % methanol for 3 s to increase the binding capacity of smaller proteins to the 
membrane and then immersed in water for 2 min to elute the methanol. The membrane 
was then equilibrated with the transfer buffer for 3 min to displace the water. Four 
pieces of filter paper that wetted with the transfer buffer was packed with the membrane 
and gel with 2 on each side. The sandwich was then put on the PhastSystem and run at 
4V, 50mA for 30 min. The membrane was briefly rinse with PBS, air-dried for 1 h and 
stored in a plastic bag at 4°C. 
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2.14 Immunodetection 
The membrane was equilibrated in blocking solution overnight at 15°C with 
gentle agitation. The blocking solution was then replaced with the diluted primary 
antibody in the blocking solution and incubated for 1 h at room temperature. The 
membrane was washed with large amount of 1 x TTBS twice for 15 min. The diluted 
secondary antibody (1:5000) in blocking solution was replaced and the membrane was 
incubated for 30 min. The membrane was washed again with large amount of 1 x TTBS 
twice for 15 min. The membrane was submerged in the developing solution (0.15 
mg/ml BCIP, 0.3 mg/ml NBT, 100 mM Tris-Cl, pH 9.0, 5 mM filtered MgCh) that 
wrapped with aluminum foil until the color developed and the reaction was stopped by 
rinsing in water. 
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Chapter III: Results & Discussion 
3.1 Isolation and characterization of IGF-II cDNA and its gene organization 
3.1.1 Introduction 
Mammalian IGF-I and IGF-II show considerable similarities to proinsulin in 
their primary and tertiary structures and are 66% identical to each other (Humbel, 1990). 
The amino acid sequences of the mammalian IGFs are highly conserved with only a 
few substitutions found and are the most conservative polypeptide (Jones and 
Clemmons, 1995; Sara and Hall, 1990). Liang et al (1996), reported the cloning of a 
carp IGF-IEa2 form cDNA as a predominant IGF form in the hepatopancreas of carp. 
IGF-II has not been identified in carp yet, in contrast to trout in which both IGF-I and 
IGF-II have been identified (Shamblott and Chen, 1992). In this study, the cDNA 
sequence encoding preproIGF-II was investigated in liver and ovary of common carp. 
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3.1.2 Results 
3.1.2.1 Generation of a fragment of the common carp IGF-II cDNA by PCR 
To isolate the common carp IGF-II cDNA, six degenerate primers within the 
conserved region of the B-, C- and A- domains were designed from the alignment of 
tilapia, barramundi, trout and salmon IGF-II cDNAs (Fig. 2.1). RT-PCR was 
performed (denaturation at 94°C for 2 min, followed by 35 cycles of 1 min at 94°C, 30 
s at 52°C, 4 min at 72°C, and finally an elongation step at 72°C for 10 min) using the 
common carp liver first strand cDNA as template and the PCR products was resolved 
on a 1.5% agarose gel as shown in Fig. 3.1. The PCR product of the appropriate size 
was purified, ligated and sequenced. 
1 2 3 
秦气〜iyy 梦4 Fig. 3.1 RT-PCR of common carp IGF-II. 
I 考 , , ， T h e degenerate primers used for 
I , RT-PCR are: lane 1, 111 and R3; lane 2, 
I \ 111 and 130. Lane 3 represents the 
^ “ � l O O b p DNA ladder. RT-PCR products 
were separated on a 1.5% agarose gel. 
The arrow indicates the putative 
common carp IGF-II cDNA fragment. 
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3.1.2.2 Isolation of the full-length common carp IGF-II cDNA by RACE 
In an attempt to obtain the full length sequence of common carp IGF-II, 5' 
RACE and 3' RACE were performed using the primers: 
GSP6F: 5 ’一GACCAACTAGCAGGTTGAGCA—3 ’； 
GSP7F: 5‘―AACAGTTGTAACCTAGCTCTT—3,； 
GSP 8R: 5 ‘―CGTCGACTGCTCAACCTGCTA—3 ‘ ； and 
GSP9R: 5‘―TACTGTTCTAGAAGAGCTAGG—3‘ (Fig. 3.2, 3.3). 
1 2 3 4 
: • 么 ' ； 二 • ^ 爆 F i g . 3.2 RACE products resolved by 
te;綠…’：彻|镇 agarose 1.5 % gel electrophoresis and 
• visualized after ethidium bromide staining. 
Lane 1 ， — e 一 Lane 2，100 bp 
DNA ladder marker; Lane 3，5 'RACE 
products performed on ovary using the primer 
GSP8R; Lane 4, 3'RACE products performed 
on ovary using the primer GSP7F. 
I 1 
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T T G G G A C A G C T C C A C A C A C C A T C T T A A C A C C A A C T G G G G A A A C T A A A C C G A C A T T C T T A A C C A A A T A C A A C A G C A C A G C A T T T T T 
T T C C C T T T T T T T T T C T T T T T T C T T T T T C T T T T T T T T T T T A T G T T G A C A T G G A G G A C C A A C T A A A A C A T C A T T C T T T G T G C C A T A C 
[ 
T T G T T T G A G A A C A G A C A G T G T C A T A A A T A A G G T C A T A A A G A T G T A C T G G T C C A T A C G A A T G C C C A T A T G C A T A C T G T T T T T / ^ A C C 
Signal peptide 
C T G T C T G C C T T C G / V A G T G G C T T C A G C T G A A A C G T T A T G C G G C G G A G A G C T G G T G G A C G C G C T A C A G T T T G T G T G T G G A G A C A G A G 
][——, B-domain 
aSPRR ^ ^ 
GRPfiF — 「tSPTF 
G T T T C T A T T T C A G T C G A C C A A C T A G C A G G T T G A G C A G T C G A C G T T C T C A ^ J - A T C G T G G G A T T G T G G A A G . ^ ^ ^ 
][ C-domain ] [ A-domain 
GSPQR ^ — 
T T G T - ~ ; : V : : C T A G C : T C : T T C T A G A A C A G T A C T G C G C T A A A C C T G C C A A G T C A G 7 \ G A G G G A C G T T T C A G C C A C A T C C C T A C A G G T C / \ T C 
][ D-domain ][ 
C C G G T G A T G C C C A C A T T A A A A C A G G A G G T C C C A A G A A A A C A T G T G A C C G T G A A A T / V T T C C A A A T A C G A C A T G T G G C A A C G A A A G G E-domain 
C C G C C C A G A G G C T A C G G A G G G G C G T C C C C G C C A T C C T G C G G G C C A i \ G A A G T T T A G G C G G C A G G C G G A G A G A A T C A G G G C C C A . A G A 
G C A A C T G C A C C A C C A C A G G C C T C T C A T C A C G C T T C C C A G C A A G C T C C C G C C C A T C C T T T T T G C A C A G . A G T C G A T G A A A A A A G A C C 
] 
A G G G G A T C ^ ^ A A G C T T T T T G T C T C T G A C G T C A T T T C T G T G G C A G T C C T C A A C ^ v A C C C T T C T T C C T T C C C C A C C C A G A C A T G C T C A C 
A C A C T C T T C C A G T T T C T A T T C T T G C G G T T T C A T T C A T C A A C A A A A A T G C A C A T C A C A A A C G A G A G G A A C A C A A T T C A G G T G A A G A 
A G C A A A G G A A A G A A C A A A G A A G C C G C A G A G C G C C G A A T G T T T C A C T G G T T T G G A G G A C / V T T G G C G C G C G A G G A A C A G C T T G A G C T 
A G C A T G A A A G A A C C C A T T C C A C C G C A T T C T C C C G A G A C A A A A T A T C T C T C T T T T A G T C C T T T T A C A T A T T A G T T T G C A C C T G T A A ‘ 
C T A T A A A G G G A C A T C C A C A C T G T A A G G A A T T G T T G T A A A A T T A G A T T C C T G T T C C A G C A C C T T G T A A T C A C A A A T G A A A A G C A G A 
G A A G A T C T G C G A A T T G C A C A T C G C C A C G G A T T A C G T C C A A G T T C T T G T T A A G T A A A T A A A A A G G C C T A T T T T T T T T A T G G A T A A A 
A A A A A A A A A A A A A 
Fig. 3.3 The composite full-length sequence of the common carp IGF-II cDNA 
as obtained by PCR, 5 'RACE and 3'RACE. The different domains are 
indicated. The amplicons of 5'RACE and 3'RACE are indicated as light 
red and blue color, respectively. The arrows indicates the orientation and 
direction of the primers designed. 
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The ORF sequence was amplified by performing RT-PCR (denaturation at 
9 4 � C for 2 min, followed by 35 cycles of 1 min at 94�C, 2 min at 58�C, 3 min at 72°C, 
and finally an elongation step at 72°C for 10 min) using either the juvenile liver, the 
female adult gill or the female adult ovary first strand cDNA as template with the 
primers GSP16F: 5'—ATGG AGGACC AACTAAAAC AT—3 ‘ and GSP17R: 
5'—TCAGAGACAAAAAGCTTTGAT—3 ‘ which designed near the start and stop 
codon, respectively (Fig. 3.4). It shows that the full-length sequence described in Fig. 
3.3 really comes from a mRNA transcript. Control PCR using the first strand cDNA 
synthesized without reverse transcription was performed to ensure there was no 
genomic DNA contamination. The cDNA sequence corresponding to the coding 
region of the IGF-II preprohormone of common carp, as indicated in Fig. 3.5, is 624 bp 
long. The deduced IGF-II protein consisted of 208 amino acids spanning the B-, C-, A-， 
D- and E-domains. The B- domain consisted of 28 amino acids (aa), the C-domain of 
15 aa, the A-domain of 21 aa, D- domain of 6 aa, and the E-domain of 92 aa. The 
sequence contains 9 cysteine residues (Cys'^ Cys'^ Cys^^ Cys54，Cys^^ Cys^^ Cys^^ 
Cys99，Cysi�8). 
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(B) 
1 2 3 4 5 6 7 8 9 10 11 12 
Fig. 3.4 RT-PCR of the full-length common carp IGF-II. 
Panel A shows the RT-PCR products of the full-length common carp IGF-II that 
resolved by agarose 1.5 % gel electrophoresis and visualized after ethidium bromide 
staining. Lanes 1, 2 and 3 are RT-PCR products using the primers GSP16F and GSP 
17R on adult female gill, juvenile carp and adult ovary, respectively; Lanes 5, 6 and 7 
are RT-PCR products using the primers GSP15F and GSP18R on adult female gill, 
juvenile carp and adult ovary, respectively; Lane 4 is the 100 bp DNA ladder marker. 
Panel B shows the control PGR reactions in the absence of the RT step. Lanes 9, 10 
and 11 are the results of control PGR with the templates prepared without reverse 
transcriptase, of juvenile liver, adult female gill, and ovary, respectively. 
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A T G G A G G A C C A A C T A A A A C A T C A T T C T T T G T G C C A T A C T T G T T T G A G A A C A G A C A G T G T C A T A A A T A A G G T C A T A A A G A T G T A C 
M E D Q L K H H S L C H T C L R T D S V I N K V I K M Y 
[ signal peptide 
T G G T C C A T A C G A A T G C C C A T A T G C A T A C T G T T T T T A A C C C T G T C T G C C T T C G A A G T G G C T T C A G C T G A A A C G T T A T G C G G C G G A 
W S I R M P I C I L F L T L S A F E V A S A E T L C G G 
] [ 
G A G C T G G T G G A C G C G C T A C A G T T T G T G T G T G G A G A C A G A G G T T T C T A T T T C A G T C G A C C A A C T A G C A G G T T G A G C A G T C G A C G T 
E L V D A L Q F V C G D R G F Y F S R P T S R L S S R R 
[ B-domain ] [ C-domain 
T C T C A A A A T C G T G G G A T T G T G G A A G A G T G T T G T T T T A A C A G T T G T A A C C T A G C T C T T C T A G A A C A G T A C T G C G C T A A A C C T G C C 
S Q N R G I V E E C C F N S C N L A L L E Q Y C A K P A 
][ A-domain ] [D-domain 
A A G T C A G A G A G G G A C G T T T C A G C C A C A T C C C T A C A G G T C A T C C C G G T G A T G C C C A C A T T A A A A C A G G A G G T C C C A A G A A A A C A T 
K S E R D V S A T S L Q V I P V M P T L K Q E V P R K H 
] [ 
G T G A C C G T G A A A T A T T C C A A A T A C G A C A T G T G G C A A C G A A A G G C C G C C C A G A G G C T A C G G A G G G G C G T C C C C G C C A T C C T G C G G 
V T V K Y S K Y D M W Q R K A A Q R L R R G V P A I L R 
E-domain 
GCCAAGAAGTTTAGGCGGCAGGCGGAGAGAATCAGGGCCCAAGAGCAACTGCACCACCACAGGCCTCTCATCACGCTTCCCAGC 
A K K F R R Q A E R I R A Q E Q L H H H R P L I T L P S 
A A G C T C C C G C C C A T C C T T T T T G C A C A G A G T C G A T G A 
K L P P I L F A Q S R * 
] 
Fig. 3.5 cDNA sequence and deduced amino acid sequence of common carp 
preproIGF-II. The different domains are indicated. The stop codon is 
indicated as ‘‘*’，. 
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3.1.2.3 Nucleotide sequence analysis 
The amino acid sequence of this common carp IGF-II was compared with 
other known IGF sequences (Fig. 3.6 and 3.7). The comparison was carried out on the 
rational of Higgins and Sharp (1988) , which is based upon an assumed evolutionary 
relationship among the sequences. More closely related sequences are presumed to 
contain fewer deletions, transitions, transversions, and other mutations than more 
distantly related ones. Alignments are constructed by progressively aligning sequences 
according to the branching order in an initial phylogenetic tree. The similarity scores 
are calculated as the number of exactly matched residues in a Wibur and Lipman (1983) 
alignment between two sequences, minus a fixed penalty for every gap (Potter 
Wickware, 1997). 
The percentage of identity between this common carp IGF-II cDNA 
sequence and IGF-II of other fish species, i.e. of salmon, barramundi and tilapia, are 
68.5%, 67.5% and 64.5%, respectively, as far as the nucleotide sequences of the coding 
regions are conserved (Table 3.1). Amino acid sequence comparison also shows that 
this common carp IGF-II has sequence identities of 70.6%, 68.7% and 63.4% in 
comparison with salmon, barramundi and tilapia IGF-II, respectively. It is thus 
concluded that this carp IGF cDNA codes for a preproIGF-II sequence. Most 
differences between the common carp IGF-II and the IGF-Iis of other fish species are in 
74 
Chapter III Isolation and characterization of IGF-II cDNA 
the signal peptide and in the E-domain. 
Barramundi 68.7% 31.1% 89.2% 73.3% 89.2% 100.0% 68.3% 
Tilapia 6 3 . 4 % 3 3 . 3 % 89.2% 53.3% 89.2% 1 0 0 . 0 % 6 3 . 2 % 
Salmon 7 0 . 6 % 3 1 . 1 % 96.4% 86.6% 96.4% 1 0 0 . 0 % 6 3 . 9 % 
Human 35.0%~~16.6% 78.5% 41.6% 78.5% 83.3% 20.2% 
Barramundi 67.5% 48.8% 80.9% 64.4% 69.8% 83.3% 73,8% 
Tilapia 6 4 . 5 % 4 0 . 7 % 79.7% 54.5% 71.4% 88.8% 69.8% 
Salmon 6 8 . 5 % 4 5 . 9 % 84.5% 69.6% 68.2% 1 0 0 . 0 % 7 3 . 1 % 
Human 4 4 . 1 % 3 3 . 3 % 61.9% 50.0% 71.4% 7 2 . 2 % 3 5 . 5 % 
Table 3.1 Nucleotide sequence and predicted amino acid sequence identities 
between the cloned common carp IGF-II and IGF-II of other species. 
Identities at the amino acid (upper) and nucleotide (lower) sequences are 
shown as percentages. 
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Salmon 
^ \99.3k 
Trout 丨 + 
Barramundi 
Tilapia ^ — — 
Common carp 
Mouse 們 � 
Rat Z Z M ^ 
Rat 85,4夸 






Fig. 3.6 Phylogenetic analysis of bovine，sheep, pig，human, mouse, barramundi 
and salmon IGF-II with the cloned common carp IGF-II. Higgins and 
Sharp sequence alignment (Higgins and Sharp, 1988) was carried out by 
DNASIS® and displayed as a map of calculated branching orders. 
Calculated matching percentages are indicated at each branch point of the 
dendrogram. 
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B-domain 
Cyprinus carpio EVASAETLCGGELVDALQFVCGDRGFYFSRPT 
6. keta E 
O. mossamhicus -M E 
Lates calcarifer -M E 
Homo sapiens AYRPS A 
C-domain 
Cyprinus carpio SRLSSRRSQNR 
O. keta - -SN 
O. mossamhicus ——GNN——P-T-
Lates calcarifer --G-N--P 
Homo sapiens � � V - R - * • - S -
A-domain 
Cyprinus carpio GIVEECCFNSCNLALLEQYCA 
O. keta R—D-N 
O. mossambicus R——D-N 
Lates calcarifer R——D-N 
Homo sapiens R—- D T 
D-domain 




Homo sapiens T 
E-domain 
Cyprinus carpio RDVSATSLQVIPVMPTLKQEVPRK-HVTVKYSKYDMWQRKAAQRLRRGVPAIL 
a keta I--MV——I--D EA 
O. mossambicus A Q EV 
Lates calcarifer A Q EV 
Homo sapiens TPP« • • •T-L—DNFP-I- LG-FFQ--T-«KQST L - - L -
E-domain 
Cyprinus carpio RAKKFRRQAERIRAQEQLHHHRPLITLPSKLPP • LFAQ• • • • —R* 
O. keta - -R VK-K AMF • V-PPTDNYV-HN 
O. mossambicus --R-YK-H--K-K-K--AIF S •V-LTTDNFV-HK 
Lates calcarifer K-K-Q--VIF S V-LTTDNYVNHK 
Homo sapiens —RRGHVL--ELE-FREAKR A--TQD-AHGGAPPEMASN-K 
Fig. 3.7 Comparison of c o m m o n carp IGF-II polypeptide sequence with that of 
Oncorhynchus keta (Palamarchuk et al” 1997), Oncorchynchus mossambicus 
(Chen et al” 1997)，Lates calcarifer fCoIlet et al.，1997a) and Homo sapiens 
(Rinderknecht and Humbel , 1978). The IGF polypeptide is divided into different 
regions: the signal peptide, and the B-, C-, A-’ D- and E-domains. The non-identical 
amino acids are shown in light blue color while the identical amino acids are indicated 
by hyphens. The gaps are indicated by “•”. The stop codon is indicated as “*，，. 
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3.1.2.4 Relationship of common carp IGF-II to common carp IGF-I and 
insulin 
A comparison in amino acid sequence between IGF-I and IGF-II in common 
carp is shown in Fig. 3.8 that illustrates the distinct nature of the two molecules. The 
alignment indicates strong amino acid conservation between the two IGFs in the B-, C-, 
A-, D-domains and in the seven cysteines, except for the first cysteine, which is present 
in the putative mature protein form and is likely to contribute to the three-dimensional 
structure through intra-protein disulfide bonding. It should be noted that almost all 
cysteines outside the regions of the putative mature protein are not conserved. In this 
analysis, the percentage of identity between the ORF of IGF-II and IGF-I cDNA 
sequences in common carp is 35.8%. Amino acid sequence comparison between 
IGF-II and IGF-I in common carp shows identities of 22.7%, 64.2%, 47.2%, 58.7%, 
38.8% and 27.7% in the signal peptide, B-, C-,A-, D- and E,domains, respectively. As 
for the common carp insulin, common carp IGF-II shows 46.4% and 38% amino acid 
identities in the B- and A- domains, respectively. 
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IGF-I PATL . -AGP A- • • -T K» • GYGP 
B-domain C-domain 
IGF-II QNRGIVEEggFNSgNLALLEQYgA—-KPAKSERDVSATSLQVIPVMPTLKQ 
IGF-I H D » • • ' Q ' ' E ' R R ' - M * • - P V * • G • T P • S • R • Q R H T D S P — - R « A « K 
A-domain D-domain 
IGF-II EVPRKHVTVKYSKYDMWQRKAAQRLRRGVPAILRAKKFRRQAERIRAQEQL 




Fig. 3.8 Amino acid sequence alignment of IGF-I and IGF-II in common 
carp. 
The identical amino acids are indicated as Gaps are indicated by 
hyphens. The stop codon is indicated as '*’，. The conserved cysteines are 
shown in black boxes. The signal peptide, B-, C-，A-, D- and E-domains 
are indicated below the sequence. 
3.1.2.5 Confirmation of the presence of IGF-II in common carp 
Northern hybridization of mRNA from common carp day 1 larvae and 
adult ovary showed the presence of multiple IGF-II transcripts (Fig. 3.9). The rat 
IGF-II gene and the human IGF-II gene are transcribed from three and four promoters, 
respectively, generating multiple transcripts (Sussenbach, 1989). It appears from our 
work that at least two transcripts with sizes approximately 1.35kb and Ikb were 
detected in common carp tissues. 
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1 2 
( A ) 4 . 4 k b - > ( B ) 
2.37 kb ~ ~ • 
1.35 k b — > � ， 、 … 
條 — 1 . 3 5 k b 
、、；J — 1 kb “ , • 
Fig. 3.9 Northern blot analysis of common carp IGF-II. 
(Panel A) About 2 )LLg of poly (A)+ RNAs from larvae (Day 1) (Lane 1) 
and ovary (Lane 2) were hybridized with the full-length sequence of the 
common carp IGF-II. Two transcripts of about 1.35 kb and 1 kb were 
detected. RNA ladder was indicated at the left. 
(Panel B) The membrane was stripped and then hybridized with 
common carp |3-actin that used as control. 
3.1.2.6 Multiple mRNA forms of common carp IGF-I and IGF-II 
RT-PCR assays were developed to detect additional size forms of common 
carp IGF-II mRNA (denaturation at 94°C for 2 min, followed by 35 cycles of 1 min at 
94�C, 2 min at 55°C, 3 min at 72�C, and finally an elongation step at 72°C for 10 min 
for amplifying the ORF; whereas denaturation at 94°C for 2 min, followed by 20 cycles 
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of 30 s at 94°C, 30 s at 55°C, 1 min al 72°C, and finally an elongation step al 72X' for 
10 min for amplifying the |3-actin). In order to confirm the identity of the bands, they 
were cloned into pGem-T Easy vector and sequenced. Two size forms of IGF-II were 
detected (Fig. 3.10). A nucleotide sequence alignment of the two size forms of IGF-II 
indicated the size difference was due to an insertion in the E-domain (Fig. 3.11). 
1 2 3 4 5 6 7 8 9 10 
L L a i A M i J f c i g i i A t — ^ & f e ^ a A i t f i i . i r i y f i I 丨I丨 i i i f t 赫ill丨 A i i i i i l l b 
(B) 零,響^ 
Fig. 3.10 IGF-II RT-PCR in different tissues of adult male common carp. 
The first strands were amplified with the primers coding for the ORF 
(Panel A) and p-actin (Panel B). Lane 1, negative control; lane 2, brain; 
lane 3, gill; lane 4, heart; lane 5, intestine; lane 6, kidney; lane 7, liver; lane 
8, muscle; lane 9, spleen; lane 10, testes. 
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a AT GGAGGACCAACTAAAACAT CATTCTTTGTGCCATACTTGTTTGAGAACAGACAGT GT CATA 
b 
M E D Q L K H H S L C H T C L R T D S V I 
a AATAAGGTCATAAAGATGTACTGGTCCATACGAATGCCCATATGCATACTGTTTTTAACCCTG 
b 
N K V I K M Y W S I R M P I C I L F L T L 
a TCTGCCTTCGAAGTGGCTTCAGCTGATyVCGTTATGCGGCGGAGAGCTGGTGGACGCGCTACAG 
b 
S A F E V A S A E T L C G G E L V D A L Q 
a TTTGTGTGTGGAGACAGAGGTTTCTATTTCAGTCGACCAACTAGCAGGTTGAGCAGTCGACGT 
b 
F V C G D R G F Y F S R P T S R L S S R R 
a TCTCAAAATCGTGGGATTGTGGAAGAGTGTTGTTTTAACAGTTGTAACCTAGCTCTTCTAGAA 
b 
S Q N R G I V E E C C F N S C N L A L L E 
a CAGTACTGCGCTAAACCTGCCAAGTCAGAGAGGGACGTTTCAGCCACATCCCTACAGGTCATC 
b 
Q Y C A K P A K S E R D V S A T S L Q V 工 
a CCGGTGATGCCCACATTA?y\ACAGGAGGTCCCAAGAAAACATGTGACCGTGAAATATTCCAAA 
b 
P V M P T L K Q E V P R K H V T V K Y S K 
a TACGACATGTGGCAACGA7VAGGCCGCCCAGAGGCTACGGAGGGGCGTCCCCGCCATCCTGCGG 
b 
Y D M W Q R K A A Q R L R R G V P A I L R 
a GCCAAGAAGTTTAGGCGGCAGGCGGAGAGAATCAGGGCCCAAGAGCAACTGCACCACCACAGG 
b 
A K K F R R Q A E R I R A Q E Q L H H H R 
a CCTCTCATCACGCTTCCCAGCAAGCTCCCGCCCATCCTTTTTGC-ACAGAGTCGATGA 
b AGAC-ACGTCAG 
a P L I T L P S K L F P I L F A Q S R * 
b L P T E R L R Q 
a 
b CCACAAGT GAAAC C AG GAT ACAT T T G CAC AGT T GAT GAAAAAAAAAAAGACTAG 
a 
b P O V K P G Y I C T V D E K K K D * 
Fig. 3.11 Nucleotide sequence alignment of two size forms of common carp 
IGF-n. “a” and “b” represents the shorter and longer size form 
respectively.The “ • ” indicates identity with each other; “ - ” indicates the 
gaps; and “*,, indicates the stop codon. Blue color indicates the difference. 
The deduced amino acid are indicated below. 
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3.1.2.7 Gene organization of the common carp IGF-II gene 
To understand the structure of IGF-II gene in common carp, genomic PGR 
was performed (Fig 3.12). Using the genomic organization of the IGF-II gene in other 
species as a working model, seven GSPs were designed in the exons. They are: 
START: 5'—ATGGAGGACCAACTAAAACAT—3 ‘； 
STOP: 5 ‘―TC AGAG AC AAA AAGCTTTGAT—3 ‘； 
I4R: 5 ‘―CATAACGTTTCAGCTGAAGCC—3 ‘； 
GSP 1 OF: 5‘―TGGTGGACGCGCTACAGTTTG—3 ’； 
GSP6F ： 5，一GACC AACTAGC AGGTTGAGCA—3 ’ ； 
GSP8R: 5 ’�CGTCGACTGCTCAACCTGCTA—3 ’ 
GSP14R: 5 ‘―GAGACAAAAAGCTTTGATCCC—3 ’. 
Genomic PCR was performed using these primers so that the introns could be 
amplified. Four different exon-containing regions were identified in the common carp 
IGF-II gene, designated exons 1-4 (Fig. 3.13). 
The common carp IGF-II gene fragments were subcloned in plasmid vectors 
pBS (SK+) and the sequences determined. It was found that all exon-intron boundaries 
contained canonical donor and acceptor splice sequences (Table 3.2). Mature common 
carp IGF-II is encoded by two exons, 2 and 3, as in other species such as man, mouse 
and sheep. The leader sequence is located in exons 1 and 2 which together encode for a 
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45 aa long signal peptide that differs from all other known IGF-II leader sequences. 
The E domain and the 3' untranslated region are encoded by exons 3 and 4. 
wmm 
圓 
Fig. 3.12 Genomic PGR of IGF-II gene in common carp. Lane 1, negative 
control; lane 2, using the primers Start and Stop; lane 3, using the primers 
Start and I4R; lane 4, using the primers GSP 1 OF and GSP8R; lane 5, using 
the primers GSP6F and GSP14R. 
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START nSPinF-y oSPhF ^ ^TOP 
E X I k EX3：： [ X D ^ j 4 _ J 
••• •  •• ： •• 
• • • • • • • : • • •• ••• •  •• : •  ; ..•. .... � ••.� 
5， r % H B I C I A I D I . � I 3， 
Fig. 3.13 Structure of the common carp IGF-II gene. Exons are depicted by 
boxes and introns and flanking regions by thin lines. The structure of the 
corresponding mRNA and the domain structure of the common carp 
preproIGF-II peptide are displayed below the gene map. The arrows 
indicated the orientation and direction of the primers designed. 
Exon Exon 5' Splice donor Intron size 3' Splice acceptor 
size (bp) (bp) 
1 2 01bp ATAAATAAGgtaaag. . -1.3 kb ccacagGTCATAAAG...exon 2 
I N K V I K 
2 152bp TATTTCAGTacgtac. . -1.4 kb TgcagtCGACCAACT...exon 3 
Y F S R P T 
3 18 0bp TTAAAACAGgtacgt. . -0.9 kb CaacagGAGGTCCCA...exon 4 
L K Q E V P 
4 754bp - - -
Table 3.2 Intron-exon organization of common carp IGF-II gene. 
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3.1.3 Discussion 
In rainbow trout, IGF-I and IGF-II are encoded by separate genes as in 
mammals. It was indicated by the absence of pattern similarity in the genomic 
Southern blot analysis using either IGF-I or IGF-II probe (Shamblott and Chen, 1992). 
In common carp, genomic Southern blot analysis revealed that three gene fragments 
hybridized with the IGF-I Ea2 cDNA probe (the Rsa I fragment coding for the B-, C-, 
A- and D-domains) in the genomic DNA digested with Hind III (Liang et al., 
unpublished data), whereas five gene fragments were hybridized with the Hind III 
digested IGF-I clone (PI) obtained from the genomic library screening (Yu et al., 
unpublished data). This difference may be due to different common carp strains as the 
library was obtained from StratageneTM whereas the genomic DNA was prepared from 
the local common carp. An alternative explanation is that there are at least two IGF 
genes in the common carp genome. Isolation of common carp IGF-II cDNA would 
help to elucidate the doubt. 
To isolate cDNA coding for IGF-II in common carp, a strategy based on 
regions of strong nucleotide conservation was used to generate the fragment. A 
multiple sequence nucleotide alignment was carried out on IGF-II sequences of four 
fish species. PGR and RACE were used. PGR products generated by 3' and 5' RACE 
procedures of about 1 kb and 500 bp were combined to generate the composite 
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full-length cDNA sequence. 
The conservation of deduced amino acid sequence in the B- and A-domains 
clearly indicates the sequence obtained is a member of the insulin gene family. The 
extensive differences between IGF-I and IGF-II in common carp as indicated by 
nucleotide and deduced amino acid comparison, and the confirmed presence of IGF-II 
in the ovary and larvae mRNA, suggest that it is a homolog of IGF-II rather than 
another IGF-I generated by alternative splicing (Rotwein et al, 1986). 
Cyprinus carpio is an evolutionary advanced teleost as salmon, tilapia and 
barramundi, and therefore the sequence homology of pro-IGF-II among these fishes is 
high when compared to those of mammals. At the amino acid level, the common carp 
IGF-II prohormone exhibits 81.5% identity to pro-IGF-II of salmon (Palamarchuk etal, 
1997), 71.7% identity to tilapia (Chen et al, 1997), 79.1% identity to barramundi 
(Collet et al, 1997a) but only 40.3% identity to human (Rinderknecht and Humbel, 
1978). Both IGF-I and IGF-II were well conserved among teleosts (Reinecke et al, 
1997). Although little information is available on the potential role of IGF-II in teleost, 
the pronounced sequence homologies may suggest a related physiological role of 
IGF-II in teleost as IGF-I. This proposal was supported by the high homologies in the 
B- and A-domains. The IGF-II D-domain actually exhibits 100% identity among all 
the different teleosts investigated. In human, the C- and D-domains interfere with the 
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binding of the IGFs to the insulin receptor as they display partial structural homology to 
the receptor binding site (Zapf et al, 1981). The function of C- and D-domains may be 
more important in the bony fish that lack the IGF-II receptor (Drakenberg et al, 1993). 
The expression of IGF-II mRNA was investigated in various tissues of adult 
carp. Two size forms of IGF-II were detected by the RT-PCR in various tissues except 
the brain. The two transcripts may be generated by alternative splicing. Most nuclear 
messenger RNA precursors in higher eukaryotes contain multiple introns, which may 
be precisely excised by RNA splicing. Alternative RNA splicing is the process that 
allows the selection of different combinations of splice sites within the mRNA 
precursors, and is part of the expression program of a large number of genes implicated 
in cell growth and differentiation (Smith and Valcarcel, 2000). Patterns of alternative 
splicing can be very complex and can involve alternative introns and exons as well as 
variations in the position of individual splice junctions. Verification can only be done 
by the nucleotide sequence determination of the entire gene. 
Three introns were amplified from the genomic DNA with a reference to the 
tilapia IGF-II gene structure. The exon/ intron organization of the IGF-II gene in 
common carp was found to be similar to that of the tilapia gene characterized (Chen et 
al , 1997). In common carp IGF-II, the first coding exon I encodes for part of the signal 
peptide sequence of 23 aa. The other 22 amino acids of the signal peptide, and the 
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amino acids of the B domain and partial C domain are encoded by the coding exon 2. 
The remaining C, A and D domains, and the first 19 amino acids of the E peptide are 
encoded by the coding exon 3. The rest of the E-domain and the 3' untranslated region 
(UTR) region are encoded by the coding exon 4. These data show that the IGF-II genes 
have assumed significantly differing structures compared to mammals such as human 
during vertebrate evolution. 
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3.2 Tissue distribution of IGF-I and IGF-II mRNA and their hormonal 
regulation 
3.2.1 Introduction 
IGF-II is produced primarily in the liver under the control of placental 
lactogen (Gray et al, 1987) during prenatal development in mammals. IGF-II 
mRNA was detected in muscle, skin, lung, intestine, thymus, heart, kidney, brain and 
spinal cords of fetal/ neonatal rats and in the brain and spinal cord of adult rats. 
IGF-II has been detected in even more tissues in human which including pancreas, 
intestine, stomach, spleen and testis. Although IGF-II seems to have a greater role in 
fetal development (Adams et al, 1983), a number of exceptions, such as maintenance 
of high mRNA levels in adult rat brain (Murphy et al, 1987) and IGF-II polypeptide 
level in human serum (Humbel, 1990). 
For the first reported non-mammalian species, rainbow trout, it was found 
that at least one form of IGF-I and IGF-II mRNA was expressed in all tissues, both in 
juvenile and adult, examined including liver, gill, pyloric caeca, spleen, kidney, heart, 
skeletal muscle, brain, ovaries and testis. The mRNA level of rtlGF-II was 
significantly higher than that of IGF-I in the juvenile pyloric caeca, as well as in the 
adult gill and pyloric caeca (Shamblott and Chen, 1993). In contrast to mammals, 
IGF-II in bony fish was expressed in a variety of extra-hepatic sites. IGF-II mRNA 
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transcripts were detected in liver, muscle, intestine, gill, heart and brain from juvenile 
barramundi (Collet et al, 1997); whereas liver, muscle, gill, heart and kidney from 
Spams (Duguay et al, 1996); and liver, pyloric and splenetic islets, stomach, small 
and large intestine, kidney, gill, testis, ovary, brain, and heart from daddy sculpin 
(Loffing-Cueni et al, 1999). The above data suggest a more complex 
developmental pattern of IGF-II mRNA and polypeptide expression. 
From studies in rats and mice, it is generally believed that IGF-II is primarily a 
fetal growth factor while IGF-I functions as a postnatal GH-dependent growth factor 
(Beck et al, 1987; Daughaday and Rotwein, 1989; DeChiara et al, 1990; Rotwein et 
al-, 1987; Stylianopoulou et al, 1988). Baker et al. (1993), who have analyzed 
growth deficiencies in transgenic mice with null mutations in the igf-I and igf-II 
genes, concluded that IGF-II acts early in mouse embryogensis whereas growth 
defects due to the absence of IGF-I appear both in prenatal and postnatal development. 
These results are in agreement with the recent findings of Duguay et al. (1996), whose 
results demonstrated that the IGF-II mRNA level was highest in larva 1 day after 
hatching and decreased thereafter; whereas IGF-I mRNA was detected in 1-day-old 
larva but there was an increase in expression in 12- and 16-day-old larva. 
In the rat and mouse, the direct relationship between increase in the levels 
of circulating GH and IGF-I mRNA had been established (LeRoith, 1991) whereas 
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the endocrine synthesis of IGF-II by the liver is not under the control of GH 
(Daughaday and Rotwein, 1989; Humbel, 1990). For the rainbow trout, the GH 
dose-dependent response of IGF-I and IGF-II mRNA levels in the liver, and only 
IGF-II in the pyloric caeca, suggested important roles of IGF-II in processes mediated 
by the endocrine and autocrine/ paracrine pathways of GH and IGF (Shamblott et al., 
1995). Whether this phenomenon is universally true for other fish species remains to 
be established. 
In order to quantify common carp tissue IGF mRNA levels, RPA was 
employed. RPA is an extremely sensitive method for the detection and 
quantification of specific mRNA in a complex sample mixture of total cellular RNA. 
The labeled RNA probe which coded for B-, C-, A- and D- domains of common carp 
IGF-II was synthesized by inserting the probe fragment into pBS SK+ vector and 
using T3, T7 RNA polymerase to generate a labeled RNA transcript of high specific 
activity. The labeled probe was then mixed with the sample RNA and incubated. 
After hybridization, the mixture was treated with ribonuclease to degrade 
single-stranded, unhybridized probe. Labeled probe that hybridized to 
complementary RNA in the sample mixture would be protected from ribonuclease 
digestion and could be separated on a polyacrylamide gel and visualized by 
autoradiography. When the probe was present in molar excess over the target 
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fragment in the hybridization reaction, the intensity of the protected fragment will be 
directly proportional to the amount of complementary RNA in the sample mixture. 
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3.2.2 Results 
3.2.2.1 RNase protection assay measurement of tissue mRNA levels in 
juvenile and adult common carp 
An RNAse protection assay (RPA) was established to quantify the mRNA 
levels of IGF-I aiid IGF-II in the tissues of two developmental stages of common carp: 
juvenile (3-4 months old, rapidly growing) and adult (20-24 months old, sexually 
mature). The adult stage was represented by 3 individual common carp whereas 
tissues from 2 juvenile common carp were pooled to represent one group in the 
juvenile stage. The tissues assayed included brain, gill, heart, intestine, kidney, liver 
and spleen from the juvenile fish; and brain, gill, heart, intestine, kidney, liver, spleen, 
muscle and gonads from adult fish. 
The IGF-I and IGF-II mRNA may cross-react with each other easily due to 
a high degree of shared nucleotide identity of 56.4% as shown in Fig. 2.4, in RT-PCR 
and Northern assays. IGF-I and IGF-II mRNA are, however, readily distinguished in 
RPA by the size of the double-stranded fragments protected from RNase T2 digestion 
of the ribo-labeled probes. Five micrograms RNA was loaded on formaldehyde 
agarose gel. The levels of 18S rRNA were determined and digitalized by the 
molecular image for each tissue in order to provide an internal standard for 
normalization purpose. 
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Fig. 3.14 Relative expression levels of IGF-I and IGF-II in various tissues of 
juvenile common carp by RPA. 
The mRNA levels, measured by RPA, were normalized with 18S rRNA 
(Panel A). Lane 1-4: Brain; lane 5-8: Heart; lane 9-12: Intestine; lane 
13-14, 27: Spleen; lane 15-18: Gill; lane 19-22: Liver; lane 23-26: Kidney. 
Riboprobes specific for IGF-I (upper) and IGF-II (lower) were used. 
Protected fragments were separated by 8% polyacrylamide gel 
electrophoresis and visualized and quantified by autoradiography (Panel 
B). Lane 1, 21: single-stranded marker; lane 2-5: Intestine; lane 6-9: 
Kidney; lane 10-13: Liver; lane 14-15, 30: Spleen; lane 16: negative 
control; lane 17-20: Brain; lane 22-25: Gill; lane 26-29: Heart. 
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Juvenile Tissue Distribution 
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Fig. 3.15 Relative expression levels of IGF-I and IGF-II in various tissues of 
juvenile common carp by RPA. 
The mRNA levels, measured by RPA, were normalized with 18S rRNA. 
Tissue types are specificed on the X-axis. Results are expressed as a 
percentage of the IGF-II mRNA value in liver and the vertical bars 
indicate SEM. 
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Male Adult Tissue Distribution 
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Fig. 3.16 Relative expression levels of IGF-I and IGF-II mRNA in 
various tissues of male adult common carp. 
The mRNA levels, measured by RPA, were normalized with 18S 
rRNA. Riboprobes specific for IGF-I and IGF-II were used. 
Tissue types are specified on the X-axis. Results are expressed as 
a percentage of the IGF-II mRNA value in liver and the vertical 
bars indicate SEM 
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Female Adult Tissue Distribution of IGF-I 
mRNA 
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Fig. 3.17 Relative expression levels of IGF-I and IGF-II mRNA in various 
tissues of female adult common carp. 
The mRNA levels, measured by RPA, were normalized with 18S 
rRNA. Riboprobes specific for IGF-I and IGF-II were used. Tissue 
types are specified on the X-axis. Results are expressed as a 
percentage of value in liver and the vertical bars indicate SEM. 
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3.2.2.2 Expression of IGF-II mRNA during larval development 
The IGF-I and IGF-II mRNA levels in total RNA isolated from pooled larva 
samples obtained at different days after hatching was assayed. Both IGF-I and 
IGF-II were detected at various time intervals. There was an increase in the 
expression of IGF-I mRNA at the 2-day-old larva with the maximum of about 1.8 
times more than the 1-day-old larva and then declined (Fig. 3.18). The IGF-I mRNA 
level of all samples from fertilized eggs and larva was greater than the unfertilized 
egg and even the ovary from sexually mature fish. The expression pattern of IGF-II 
mRNA from 1-day-old to 1-month-old larva is similar to that of IGF-I but the 
amounts expressed are less. 
The effect of possible interactions between nutrition and developmental age 
was also studied. The IGF-II mRNA levels from pooled larva samples in fed or 
fasted fish were assayed. It was found that the IGF-II mRNA level in the fed group 
was greater than the fasted group except for the 8-day-old larva (Fig. 3.19). 
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Fig. 3.18 Relative expression of IGF-I and IGF-II mRNA in common carp 
larva. 
Total RNA (50 |ig) isolated from pooled larva samples, aged day 1 to 
30 after hatching, unfertilized egg (UF), fertilized egg (F) and ovary 
from adult carp were assayed for IGF-I and IGF-II by RPA The 
relative IGF-II mRNA amount found in day-1 larva was arbitrarily set 
at 100%. The vertical bars indicate SEM. Differences between the 
levels of IGF-I and IGF-II mRNA were determined by the student 
t-test. Asterisks denote significant differences (**P < 0.01; ***P < 
0.001). 
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Fig. 3.19 Relative expression levels of IGF-II niRNA from the pooled fed 
and fasted larvae samples in common carp. 
Total R N A ( 5 0 ).ig) isolated from pooled larva samples, aged day 1 to 
30 arter hatching, unfertilized e g g and fertilized egg were assayed for 
IGF-Il by RPA Leve l s o f IGF-II m R N A in fed {}•) and fasted (IJF) 
lar\a were assayed on day 4, 6 and 8 after hatching The relative 
KiF- l l m R N A amount found in day-1 lar\a u a s arbitrarily sci at 
100�o 
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3.2.2.3 Effect of GH on IGF-I and IGF-II mRNA levels in brain and liver 
of juvenile common carp 
The effects of GH on IGF-I and IGF-II mRNA levels in brain and liver were 
examined by injecting juvenile common carp with recombinant porcine GH at 1, 10 
and 50 \xglg body weight. After 12 h of the injection, RPA was then employed to 
simultaneously measure IGF-I and IGF-II mRNA levels in the tissues. Results are 
shown in Fig. 3.20. Relatively high levels of IGF mRNA were produced in the liver 
(Fig. 3.22) which is the main endocrine source of serum IGF. Both levels of IGF-I 
and IGF-II mRNA increased significantly in response to i.p injection of pGH with 6 
fold and 3.5 fold over the sham injected controls in brain at 1 jug/g body weight 
respectively; whereas in liver, a dose of 1 jug/g body weight caused IGF-I and IGF-II 
mRNA levels to rise significantly (p < 0.05) with 2.8 and 1.75 fold over the sham 
injected control respectively (Fig. 3.21). The increased expression of both IGF-I and 
IGF-II appeared in a dose-dependent manner. Another interesting finding was that 
IGF-II mRNA showed more remarkable response in brain than liver (Fig. 3.22) 
although the endogenous IGF-II mRNA in liver was more than that in brain. 
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Fig. 3.20 Regulation of IGF-I and IGF-II mRNA level by GH in brain and liver 
of juvenile common carp. 
The mRNA levels, measured by RPA, were normalized with 18S rRNA 
(Panel A). Twelve h after the injection with different doses of pGH, 
brain (lane 1-12) and liver (lane 13-24) were collected and total RNA were 
prepared. Riboprobes specific for IGF-I and IGF-II were used. 
Protected fragments were separated by 8% polyacrylamide gel 
electrophoresis and visualized and quantified by autoradiography (Panel 
B) in brain (Upper) and liver(lower). Lane 1, 4: single-stranded marker; 
lane 2: IGF-II probe only; lane 3: IGF-I probe only. 
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In vivo GH induction on IGF-II 
mRNA in the brain and liver of 
juvenile common carp 
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Fig. 3.22 Regulation of IGF-II mRNA levels by GH in brain and liver of 
common carp. 
Juvenile common carp were injected with PBS as control and different 
doses of recombinant pGH (1 and 50 jug/g body weight). After 12h 
of injection, 50 jig total RNA were then extracted and the IGF-II 
mRNA levels were measured by RPA Results are expressed as a 
percentage of the control value and the vertical bars indicate SEM. 
Statistical difference as indicated with * P value < 0.05, compared with 
the respective control group. 
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3.2.3 Discussion 
The expression level of many commonly used internal controls such as 
glyceraldehydes-3-phosphate dehydrogenase (GAPDH) and p-actin often varies in 
different tissues. The least variant of the potential internal controls is rRNA which 
was used in our experiments. Ribosomal RNA is commonly believed to be less 
variable with treatment conditions and an independent estimate of its variation can be 
derived by comparing total RNA yield to cell number or DNA yield. Furthermore, 
in this type of experiment, it is typically the appropriate loading control because the 
assumption that rRNA does not vary is made when RNA is loaded by quantity. A 
comparison of RNA quantification by optical scanning of a Northern blot stained with 
ethidium bromide and subsequently probed with GAPDH was done by Eykholt et al 
(2000). In the experiment, the sensitivity towards the image signal of 18S was much 
greater than that of GAPDH. 
In the RPA assay of various tissues in the juvenile and adult common carp, 
the results show that all fish organs which had been demonstrated to express IGF-I 
mRNA also express IGF-II mRNA. The local production of IGF-II in many organs 
indicates that IGF- II is involved in organ-specific functions in a paracrine/autocrine 
manner as suggested by Loffmg-Cueni et al. (1999). 
The greatest IGF-I and IGF-II mRNA abundance was found in liver except 
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that gill was the site of the greatest IGF-II mRNA abundance in the female adult carp. 
In fish, gill, along with kidney, are the main excretory organs. Fish do have kidneys 
and do produce urine but the main role of the kidneys is to regulate body-water 
content. 
The IGF-II mRNA level was higher than that of IGF-I in all tissues 
examined in juvenile carp except liver; whereas the IGF-II mRNA level was higher 
than that of IGF-I in brain, gill, heart, kidney and muscle but vice versa in liver, 
spleen and testis of the male adult carp. This may give some insights regarding the 
role of IGF-II in the fetal development of teleost, in agreement with the findings in rat 
(Adams et al, 1983). 
As shown in Fig. 3.18, both IGF-I and IGF-II mRNA levels of fertilized 
eggs were greater than that of unfertilized egg. This is in agreement with the results 
in the rainbow trout that both IGF-I and IGF-II were found during the embryonic 
development (Greene and Chen, 1997). In tilapia, Schmid et al. (1999) suggested 
that both IGF-I and IGF-II were involved in the maturation of bony fish oocytes and 
in granulosa cell proliferation and differentiation in a paracrine/ autocrine manner in 
the absence of IGF-II/ M-6-P receptor (Drakenberg et al, 1993). The role of IGFs in 
the regulation of fetus development in common carp warrants further investigation. 
The preliminary data from the present study (Fig. 3.19) showed that the IGF-II 
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mRNA level in the fed carps were higher than that of fasting postnatal carps. This 
may suggest that fasting depressed the levels of IGF-II in postnatal common carp. 
The RPA results of relative hepatic and non-hepatic IGF-I and IGF-II 
mRNA levels in common carp are illustrated in Fig. 3.21. The results showed that 
the in vivo injections of GH increased both hepatic IGF-I and IGF-II mRNA levels by 
an average of approximately 330% and 250% (P < 0.05) respectively at 10 jug/ g body 
weight; whereas in non-hepatic tissue, brain, the in vivo injections of GH also 
increased both IGF-I and IGF-II mRNA levels by an average of approximately 450% 
and 350% (P < 0.05) respectively at 10 jug/ g body weight. 
It has been well documented that in bony fish, hepatic IGF-I expression is 
regulated by GH (Cao et al, 1989; Duan et al, 1993) but no effect on extra-hepatic 
tissues (Duan et al, 1994; Duguay et al, 1994). On the other hand, the information 
about the effect of GH on IGF-II expression in bony fish is not consistent. No effect 
was found in the gilthead seabream (Duguay et al, 1996) but in the rainbow trout, GH 
increased IGF-II mRNA levels in the liver and in extra-hepatic tissues, such as pyloric 
caeca (Shamblott et al., 1995) and testes (Perrot and Funkenstein, 1999). In rainbow 
trout testis, the stimulatory effect of GH on IGF-I expression was also found (Perrot 
and Funkenstein, 1999). In the present study, the GH dependence of IGF-I and 
IGF-II suggests that IGF-I and IGF-II may serve as mediators of GH in tissues, at 
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least in the brain and liver of common carp. 
In Fig. 3.22, high dosage of GH (50 \ig/ g body weight) in brain showed 
significant induction (P < 0.05) on IGF-II mRNA level but its induction on liver was 
insignificant. Moreover, the fold of induction of GH on brain was greater than that 
on liver (Fig. 3.21). This may be due to tissue specific response by different 
regulation mechanisms. Hypophysectomized rats decreased serum GH levels with a 
concurrent 8-10 fold decrease in IGF-I mRNA in the liver and pancreas and a 4-5 fold 
decrease in brain IGF-II mRNA, as well as a decrease in IGF-I serum levels. Four h 
after i.p. GH injection, liver and pancreas IGF-I mRNA levels returned to normal but 
brain IGF-II mRNA was not restored. A 50% increase in brain IGF-II mRNA was 
seen 8 h after GH injection into the lateral ventricle (Hynes et al, 1987). 
Implantation of a GH secreting tumor cell line (GH3) into adult rats resulted in a 4-6 
fold increase in skeletal and cardiac muscle IGF-II mRNA but no increase in liver 
IGF-II mRNA (Turner et al, 1988). 
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3.3 Recombinant common carp IGF-II expressed in E. coli 
3.3.1 Introduction 
Although a number of biological activities have been attributed to IGF-II, 
which are related to the insulin-like activity or the mitogenic activity of this growth 
factor (Froesch et al, 1985; Zapf et al, 1978), its physiologic role remains unknown. 
The recent cloning of IGF-II cDNAs from fish (section 3.1) along with the 
protein sequence reported for chicken IGF-II (Kallincos et al, 1990) suggests that the 
IGF-IIs share a long phylogenetic history (Upton et al, 1997). The similarities in 
primary, secondary and tertiary structure of not only the IGFs, but also of pro-insulin, 
have led to suggestions that these proteins originated from a common precursor. The 
deduced amino acid sequence from the cDNA of Atlantic hagfish, a representative of 
vertebrate class, Agnatha (Nagamatsu et al, 1991), revealed a protein that was very 
different from insulin and as similar to IGF-I as it was to IGF-II, hence demonstrating 
that the divergence of the IGF and insulin genes occurred prior to the separation of the 
Agnatha from the main line of vertebrate evolution approximately 550 million ago. 
While there is considerable structural evidence that the IGFs share a long evolutionary 
history, little is known about the conservation of IGF function. 
To investigate the physiological functions of IGF-II in fish as the presence of 
IGF-II in fish is confirmed, it is important to obtain sufficient quantities of IGF-II 
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peptide for both bioassay and development of RJA, radioreceptor assay and ELISA. 
Since purification of IGF-II in sufficient quantities for biochemical studies has been 
hindered by its low abundance from natural sources such as serum and liver tissue, 
availability of the common carp IGF-II cDNA makes it possible to obtain the 
corresponding protein through recombinant DNA techniques. This approach is 
taken with the goal of producing biologically active recombinant common carp IGF-II 
that must accumulate in the cell at sufficiently high levels for subsequent use in 
physiological studies on fish. 
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3.3.2 Results 
3.3.2.1 Production of recombinant common carp IGF-II 
The common carp IGF-II was produced as a recombinant protein in bacteria. 
The pRSET A expression vector (Invitrogen™) used is shown in Fig. 3.23. The 
2897 bp plasmid contains the T7 promoter sequence, an ATG translation initiation 
codon, a series of six histidine residues that function as a metal binding domain in the 
recombinant protein, a transcript stabilizing sequence from gene 10 of phage T7, the 
enterokinase cleavage recognition sequence and 70 amino acid residues of common 
carp IGF-II (B-, C-, A- and D-domain as in the native mature form) that was inserted 
by sticky-end ligation (BamHI/ PstI). 
E. coli BL21(DE3) and C41(DE3) cells transformed with pRSET A were 
isolated and grown at 37°C to early exponential phase (Abseoo 二 0.4-1.0). After 5 h 
at 37°C with the addition of IPTG, the cells were lysed in the sample buffer and the 
lysates were subjected to SDS-PAGE under reducing condition. Recombinant 
common carp IGF-II expressed poorly in BL21(DE3), were over-produced 
successfully in the mutant host C41(DE3) (Fig. 3.24). The pellet portion was 
isolated for purification (Fig. 3.25). 
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Fig. 3.23 Schematic representation of the construct engineered for expression of 
the common carp IGF-II in E. coli. 
The expression plasmid, pRSET A, contains a T7 promotor, 6 x His tag, 
T7 gene 10 leader, anti-Xpress™ epitope, multiple cloning site (MCS), T7 
transcription terminator, an origin of replication (fl ori) and ampicillin 
resistance gene (ORF). 
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Fig. 3.24 Production of recombinant common carp IGF-II with different strain 
of E. coli. 
Cell lysates were separated in a coomassie blue stained Tris-HCl/ Tricine 
acrylamide gel. Expression of common carp IGF-II in two host cells, 
BL21(DE3) (Panel A) and C41(DE3) (Panel B) was compared. Lane 1 
represents the E. coli lysate before addition of IPTG; whereas lane 2 
represents the E. coli lysate 24 h (BL21(DE3)) and 22 hr (C41(DE3)) after 
induction of recombinant protein expression by addition of IPTG Lane 
3 was the low-range protein size standards from GIBCOBRL 
1 2 Fig. 3.25 Tricine SDS PAGE analysis of 
更 ^ J U j t�tal cell protein from E. coli. 
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3.3.2.2 Purification of recombinant common carp IGF-II 
The recombinant common carp IGF-II protein expressed in E. coli C41(DE3) 
was purified using Invitrogen's ProBond™ resin as the vector pRSET A contained six 
histidine residues in the N-terminal peptide which had a high affinity for Probond™ 
resin. Four fractions of 400 jul each were collected (Fig. 3.26). The first and 
second fractions from purification of common carp IGF-II was separated once again 
by the 20% SDS-PAGE and then transferred to a PVDF membrane with the 
PhastSystem, Pharmacia B i o t e c h ™ . The immunoblot was stained with rabbit 
anti-human IGF-II polyclonal antiserum diluted 1:10000. The IGF-II 
immunoactivity of about 7kDa was obtained. The immunoblot was also stained with 
rabbit anti-human insulin polyclonal antibody and rabbit anti-salmon IGF-I polyclonal 
antibody and no immunoactivity was obtained. 
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Fig. 3.26 Purification of recombinant common carp IGF-II. 
The complete coding region of the mature IGF-II was cloned in-frame into 
the pRSET A vector by sticky-end ligation. Proteins were separated in a 
coomassie blue stained 20o/o SDS-PAGE gel. Lane 1, the E. coli lysate 
before addition of IPTG; Lane 2, unpurified E. coli lysate 24 h after 
induction of recombinant common carp IGF-II expression by addition of 
IPTG; lane 3, low-range protein size standards from GIBCOBRL; (lane 
4-7) eluted fractions of purified expressed common carp IGF-II. 
Approximate locations of molecular weight markers (kiloDalton) are 
shown on the left. 
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3.3.2.3 Immunodetection 
The first and second fractions from purification of ccIGF-II was separated 
once again by the 20% SDS-PAGE and then transferred to a PVDF membrane with 
the PhastSystem, Pharmacia Biotech™. The immunoblot was stained with 
anti-human rabbit IGF-II polyclonal antiserum diluted 1:10000. The IGF-II 
immunoactivity of about 7 kDa was obtained (Fig. 3.27). The immunoblot was also 
stained with anti-human rabbit insulin polyclonal antibody and anti-salmon rabbit 
IGF-I polyclonal antibody and no immunoactivity was obtained. 
SDS-PAGE Immunoblot 
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Fig. 3.27 SDS-PAGE (lanel-2) and immunoblot (lane 3-4) of IGF-II in common 
carp. The immunoblot was stained with anti-human IGF-II polyclonal 
antiserum diluted 1:10000. Lane 1 and 2 contains the purified fraction of 
recombinant IGF-II in common carp. 
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3.3.3 Discussion 
Both Fig. 3.26 and 3.27 suggested that the recombinant common carp IGF-II 
was successfully produced in bacteria. Many problems were encountered and 
conditions were tried and modified as the size of the protein is small (~7 kDa). The 
selection of C41(DE3), a mutant host of BL21(DE3) that expresses the 
oxoglutarate-malate carrier protein from mitochondrial membrane, was employed in 
order to overcome the toxic effects associated with over-expression. This overcomes 
the problem of bacterial cell death when the recombinant protein is produced as 
inclusion bodies at an elevated level (Miroux and Walker, 1996). 
Also, tricine gel was chosen as an alternative to the high percentage 
Tris-glycine gel normally used to resolve small size proteins. The resolution of 
small proteins were hindered by the continuous accumulation of free dodecyl-sulfate 
(DS) ions from the SDS sample and running buffers in the stacking gel. This 
build-up of DS led to convective mixing of the DS ions with the small proteins, 
causing fuzzy bands and decreased resolution. The mixing of the DS ions with the 
small proteins would also interfere with the fixing and subsequent staining process. 
Schaegger and von Jagow (1987) replaced the trailing glycine ion with a fasting 
moving tricine trailing ion to solve the problem. The small proteins, which ran with 
the stacked DS in the Tris-glycine system would separate from DS in the tricine gel 
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system, resulting in sharper, cleaner bands and better resolution. 
To study the biological activities of common carp IGF-II that mediated by 
polypeptides binding to the IGF receptor and modulated by IGF binding proteins 
acting on the stability and availability of IGF, protein based research component will 
be required. As the heterologous assay systems, such as mammalian RIA and 
radioreceptor assays, used to detect IGF-I and IGF-II like reactivity were not fully 
validated (Bautista et al, 1990; Daughaday et al, 1985; Drakenberg et al, 1989; 
Wilson and Hintz, 1982) and the use of heterologous peptides as reference standards 
makes quantification of native IGF-I/ -II more difficult, having ccIGF-I/ -II and 
antibodies raised against this peptides will increase the probability of developing a 
valid RIA. The peptides will facilitate the addressing questions of circulating and 
tissue levels of IGFs, their localization, receptor-binding and interaction with binding 
proteins. The recombinant common carp IGF-II produced in the present study is just 
the preliminary step. 
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Chapter IV: General conclusion 
The focus of interest on hormones in bony fish is recently noticeable, 
probably due to the considerable commercial value as scientific results on growth 
regulation have a major impact on the aquaculture industry (Reinecke and Collet, 
1998). Common carp {Cyprinus carpio), a local fish species, is chosen as the study 
model in order to study the IGF system in fish. 
The identification of IGF mRNA and the determination of their respective 
levels in various tissues are the fundamentals to establish their biological functions in 
fish. The common carp IGF-IEa2 cDNA had been successfully isolated in our 
laboratory previously (Liang et al, 1996). In the present study, we have successfully 
isolated the IGF-II full-length cDNA sequence by a combination of PGR and RACE 
techniques from the common carp liver and ovary, which were believed to be the sites 
of the highest expression level. The mammalian IGF-II gene undergoes alternative 
RNA processing to generate mRNA transcripts from 1 to 6 kb from what appear to be 
at least 3 developmental and tissue-specific promotors. In common carp, we found 
that most tissues possess two transcripts in adult. Do different transcripts generated 
in different stages carry out different functions by a developmental stage-specific 
factor regulation as suggested in the study of salmon (Palamarchuk et al, 1997)? 
Or are they generated and regulated by different promotors as in mammals? This 
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remains to be investigated. 
The determination of the relative expression levels of IGF-II in various 
tissues of the common carp in two developmental stages, juvenile and adult, and in 
both sexes were performed by RPA. The results showed that all fish organs express 
IGF-I mRNA also express IGF-II mRNA. The local production of IGF-II in many 
organs indicates that IGF-II is involved in organ-specific functions in a paracrine/ 
autocrine manner as suggested by previous reports (Loffing-Cueni et al, 1999; 
Schmid et al, 1999). Although bony fish lack the IGF-II/ M-6-P receptor 
(Drakenberg et al, 1993), similar effects may be exerted by IGF-II mediated via the 
type I IGF receptor. This hypothesis is supported by the recent finding that the 
stimulatory effect of IGF-II on steroid production on cultured human granulosa cells 
was mediated via the type I IGF receptor (Willis et al, 1998). Nevertheless, the 
paracrine/ autocrine effect should be further studied by isolating the IGF receptor in 
different tissues. 
A study of postnatal sheep (Hua et al, 1995) indicated that plasma IGF-I 
and IGF-II are differentially regulated by nutrition, GH and developmental stage. 
Results from the present study demonstrate that GH administration stimulated an 
increase in IGF-I and IGF-II levels in common carp. GH dependence of IGF-I and 
IGF-II suggests that IGF-I and IGF-II may serve as mediators of GH in tissues, at 
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least in the brain and liver of common carp. On the other hand, fasting depressed the 
expression levels of IGF-II. The GH/ nutrition interaction for IGF-II expression as 
indicated in the present study suggest that GH has a greater stimulating effect on 
IGF-II level in fed rather than fasted postnatal common carp. Common carp offers 
an excellent alternative to mice for studying the IGF function during the embryonic 
development because its ease of embryo manipulation, its semi-transparent eggs for 
observation and its short generation time. 
In summary, 7 inter-related findings can be concluded from the present study: 
(1) a full-length IGF-II cDNA sequence has been obtained from common carp, 
Cyprinus carpio; (2) Northern blot analysis of the common carp larvae and ovary 
showed 2 transcripts of IGF-II of different sizes; (3) the exon/ intron organization of 
the common carp IGF-II gene was found to be similar to other fish species i.e. the 
mature IGF-II protein is encoded by two exons (exons 2 and 3 in fish; exons 4 and 5 
in rodents; exons 8 and 9 in sheep; and exons 7 and 8 in man (Sussenbach et al., 
1992)); (4) expression of IGF-I and IGF-II mRNA was found in all fish organs 
examined in juvenile and adult by RPA; (5) IGF-II mRNA level in the fed carps were 
higher than that of fasted postnatal carp; (6) both IGF-I and IGF-II in common carp 
showed GH dependence in juvenile hepatic and non-hepatic tissues; (7) the reading 
frame of B-, C-, A- and D-peptides of common carp IGF-II has been inserted in an 
1 2 2 
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expression vector pRSET A for recombinant expression of common carp IGF-II 




Ca/g lyce ro l bu f fe r : 0 . 6 M CaCl., 10ml 
0 . 5 M Pipes pH7 .0 2 m l 
G lycero l 15ml 
Water 73ml 
Fi l ters sterilize using 0.22|um filter. 
E t h i d i u m b romide (EtBr) , l O m g / m l : E t h i d i u m bromide 0.2g 
D is t i l l ed water 19.8ml 
Store at r o o m temperature and prevent f r o m 
exposure to l ight. 
Ethy lenediamine tetraacetic acid ( E D T A ) , 0.5M: N a ^ E D T A ^ S H s O 93.05g 
Dis t i l led water 
M i x up to 300ml 
Ad jus t the p H to 8.0 w i t h l O M 
N a O H . 
Ad jus t the f inal vo lume to 500ml and 
autoclave. 
Store at r o o m temperature. 
Gel - load ing buf fer , D N A : Sucrose 4g 
B romopheno l blue 0.025g 
Xylene cyanol 0.025g 
Dis t i l led water 10ml 
Store at 4°C. 
G r i nd ing buf fer : O . l M T r i s 
0 .05M N a . E D T A 
0 .2M NaC l 
1% SDS 
Isopropyl-P-D-th iogalactopyranoside ( IPTG) , lOOmM: I P T G 238mg 
Sterile water 10ml 
Fil ter sterilizes using 0.22\xm 
filter. 
Store in 1ml aliquots at -20°C. 
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Phosphate-buf fered saline (PBS): N a C l 8g 
K C l 0.2g 
N a . H P O , 1.44g 
0.24g 
D is t i l l ed water 900ml 
Ad jus t p H to 7.4 w i t h I M H C l and add water to a 
f inal vo lume of" I L 
Autoc lave and store at r o o m temperature. 
Sod ium acetate, 3M: Sod ium acetate*3H20 40.8g 
D is t i l l ed water 80ml 
Ad jus t to desired p H w i t h glacial acetic acid 
A d d water to a f inal vo lume o f 100ml, autoclave 
Store at r o o m temperature. 
Sod ium hydrox ide ( N a O H ) , lOM: N a O H 40g 
D is t i l l ed water 100ml 
Store i n a plastic container at r o o m temperature. 
T A E buf fer , SOX: Tr is base 242g 
Sod ium acetate^SH^O 136. Ig 
N k 2 E D T A . 2 H 2 〇 19g 
D is t i l led water 700ml 
Ad jus t p H to 7.2 w i t h acetic acid. 
A d d water to a f inal vo lume o f I L . 
T B E buf fer , lOX: Tr is base 54g 
Bor ic acid 27.6g 
N a ^ E D T A . S H p 9.3g 
A d d water to a f inal vo lume o f 500ml. 
Tr is-Cl , 2M , pH7.4: Tr is base 242.2g 
Dis t i l led water 700ml 
Ad jus t the p H by concentrated HC l . 
A d d water to a f inal vo lume o f I L . 
Sterilize by autoclave and store at r o o m temperature. 
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X-ga l (5-bromo-4-ch loro-3- indo ly l -p-D-ga lac tos ide) : X -ga l 2 0 m g 
2 0 m g / m l D i m e t h y l f o r m a m i d e 1ml 
Store at -20°C i n glass container. 
Radioactive DNA probe synthesis, hybridization and wash solution 
Denhard t ' s solut ion, 100 x: Po lyv iny lpyr ro l idone (PVP) lOg 
Bov ine serum a lbumin (BSA) lOg 
F ico l l 400 lOg 
D is t i l l ed water 460ml 
Store at -20°C in 50ml aliquots. 
Hyb r id i za t i on buf fer : lOOx Denhardt 's Solut ion 5ml 
20x SSC 30ml 
10% SDS 5ml 
D is t i l l ed water 10ml 
Freshly prepare on the day to use. 
Blotting 
A lka l i transfer buf fer : 0.4 M sod ium hydrox ide 
B lock ing Solut ion: Sk im m i l k powder 0.5g 
I X T T B S 10ml 
Dena tu r ing Solut ion: 1.5 M N a C l 
0.5 M N a O H , sterilize by autoclave. 
N B T : N B T 5 0 m g / m l 
D imethy to rman ide 70% 
Neut ra l iza t ion Solut ion: 1 .5M N a C l 
0.5 T r i s -HC l , p H 7.2 
0.001 M E D T A , sterilize by autoclave. 
Neut ra l izat ion transfer buf fer : 20 x SSC 
3 M N a C l 
0.3 M sodium citrate 
Sterilize by autoclave. 
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S o d i u m dodecy l sulfate (SDS), 10% (w/v)： SDS lOOg 
D is t i l l ed water 800ml 
W a r m the so lu t ion to 50°C to dissolve. 
A d d water to a f ina l v o l u m e to I L . 
SSC bu f fe r , 20X : N a C l 175.3g 
T r i s o d i u m c i t ra te*2H2〇 88.2g 
D is t i l l ed water 800ml 
Ad jus t the p H to 7.0 by l O M N a O H . 
A d d water to a f inal v o l u m e o f I L 
Steri l ize by autoclave. 
Western b l o t transfer bu f fe r , I X : T r is Base 2 5 m M 
Glyc ine 1 9 2 m M 
M e t h a n o l 2 0 % 
Preparation and resolution of RNA 
Forma ldehyde gel load ing bu f fe r : G lyce ro l 50% 
E D T A , p H 8.0 I m M 
B r o m o p h e n o l blue 0 .25% 
Xy lene cyanol F F 0.25% 
M O P S , bu f f e r 5x: 3 - (N-morpho l ine )p ropanesu l fon ic acid (MOPS) 20.95g 
Sod ium acetate 3.4g 
N a a E D T A G H p 1.9g 
D is t i l l ed water m i x up to I L 
Autoc lave and store at r o o m temperature. 
Polyactylamide gel electrophoresis 
A n o d e bu f fe r (Tnc ine S D S - P A G E ) : Tr is 19.3824g 
Ad jus t the p H to 8.9 by H C l 
Ac ry lamide Solut ion, 30:0.8，40% ( w / v ) : Acry lamide 30g 
Bis-acrylamide 0.8g 
D is t i l l ed water m i x up to 100ml 
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B r o m o p h e n o l blue, 10% ( w / v ) : B r o m o p h e n o l blue I g 
D is t i l l ed water m i x up to 10ml 
Store at r o o m temperature. 
Cathode bu f fe r (Tr ic ine S D S - P A G E ) : SDS 0.2g 
Tr i c ine 3.584g 
T h s 2.4228g 
Ad jus t the p H to 8.25 
Coomassie Blue Stain: Coomassie Br i l l ian t Blue 0.05% 
Acet ic A c i d 10% 
Methano l 40% 
Dis t i l l ed water 50% 
Desta in solut ion: Me thano l 40% 
Acet ic acid 10% 
Dis t i l l ed water 50% 
Elect rode Buf fe r , l O X (SDS-PAGE) : Tr is Base 6g 
Glyc ine 28.8g 
SDS, 10% 10ml 
D is t i l l ed water m i x up to 100ml 
Ge l Bu f fe r (Tr ic ine SDS-PAGE) : Tr is 3.6342g 
SDS 0.03g 
D is t i l l ed water m ix up to 10ml 
Ad jus t the p H to 8.45 by H C l . 
Lowe r Bu f fe r (SDS-PAGE) : Tr is Base 18.15g 
Dis t i l led water m ix up to 100ml 
Ad jus t the p H to 8.8 by H C l . 
Sample Buf fe r , 2x, 8ml (SDS-PAGE) : Upper buf fer 1ml 
Glycero l 1ml 
10% SDS 1ml 
2-P-mercaptoethanol 0.1ml 
0.05% Bromopheno l blue 0.2ml 
D is t i l led water 4.7ml 
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Sample Bu f fe r , 1m l (Tr ic ine S D S - P A G E ) : Tr is 0.0121g 
Glycero l 0 .19048ml 
SDS 0.08g 
2-p-mercaptoethano l 0 .03604ml 
B r o m o p h e n o l blue Trace amoun t 
D is t i l l ed water 1ml 
Solu t ion A (20% polyacrylamide): Acry lamide 96.5g 
Bis-acrylamide 33.5g 
Urea 233.5g 
5 x T B E 100ml 
D is t i l l ed water m i x up to 500ml 
Solut ion B (Urea mix) : Urea 233.5g 
5 x T B E 100ml 
D is t i l l ed water m ix up to 500ml 
TBS: Tr is , p H 8.0 l O m M 
N a C l I S O m M 
T T B S , I X : Tr is Base 2 0 m M 
N a C l 0.8% 
Tween 20 0.1% , 
Upper Bu f fe r (SDS-PAGE) : T n s Base 6g 
D is t i l led water m ix up to 100ml 
Ad jus t the p H to 6.8 by H C l 
Bacterial growth 
L B Agar: T ryp tone lOg 
Yeast Extract 5g 
N a C l 5g 
Agar 15g 
Dis t i l led Water mix up to I L 
Sterilize by autoclave, cool down and pour in to culture dish 
•LB broth: T ryp tone lOg 
Yeast Extract 5g 
NaC l 5g 
Dis t i l led Water m ix up to I L 
Sterilize by autoclave. 
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